<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 3.6c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: XBRL OPRX.xfr; Date: 2014%2D04%2D11T17:16:45 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:us-roles="http://fasb.org/us-roles/2013-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:OPRX="http://OPRX/20131231">
    <link:schemaRef xlink:href="oprx-20131231.xsd" xlink:type="simple" />
    <xbrli:context id="From2013-01-01to2013-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2008-04-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2008-04-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-04-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-04-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-01-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-01-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-01_custom_NorthCoastAdvisorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis">OPRX:NorthCoastAdvisorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-01_custom_NorthCoastAdvisorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis">OPRX:NorthCoastAdvisorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-07-12_custom_NorthCoastAdvisorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis">OPRX:NorthCoastAdvisorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-07-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-09-20_custom_SeparationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis">OPRX:SeparationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-09-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-01-02_custom_SeparationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis">OPRX:SeparationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-01-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2008-01-01to2008-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2008-01-01</xbrli:startDate>
        <xbrli:endDate>2008-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2010-01-01to2010-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2010-01-01</xbrli:startDate>
        <xbrli:endDate>2010-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-03-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-03-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-09-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-09-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-05-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-05-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-11-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-11-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-29_us-gaap_SeriesAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_SeriesAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_SeriesAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-29_us-gaap_SeriesBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_SeriesBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_SeriesBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-05-31_ThreeEmployeesStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">OPRX:ThreeEmployeesStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_ThreeEmployeesStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">OPRX:ThreeEmployeesStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-05-30_ThreeEmployeesStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">OPRX:ThreeEmployeesStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-05-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_TwoEmployeesStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">OPRX:TwoEmployeesStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_TwoEmployeesStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">OPRX:TwoEmployeesStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-11-21_IndividualStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">OPRX:IndividualStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-11-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_IndividualStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">OPRX:IndividualStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_FourNonEmployeesStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">OPRX:FourNonEmployeesStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-06-30_FourNonEmployeesStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">OPRX:FourNonEmployeesStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_NonEmployeeStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">OPRX:NonEmployeeStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_NonEmployeeStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">OPRX:NonEmployeeStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_TwoEmployeesStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">OPRX:TwoEmployeesStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_IndividualStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">OPRX:IndividualStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_NonEmployeeStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">OPRX:NonEmployeeStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-01_custom_NorthCoastAdvisorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis">OPRX:NorthCoastAdvisorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_us-gaap_DeferredCompensationShareBasedPaymentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_DeferredCompensationShareBasedPaymentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_DeferredCompensationShareBasedPaymentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-07-01to2011-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-07-01</xbrli:startDate>
        <xbrli:endDate>2011-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-10-30_custom_SixEmployeesStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">OPRX:SixEmployeesStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-10-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_SixEmployeesStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">OPRX:SixEmployeesStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-11-08_custom_TwoNonEmployeeStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">OPRX:TwoNonEmployeeStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-10-01to2013-12-31_custom_TwoNonEmployeeStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">OPRX:TwoNonEmployeeStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-10-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2013-12-31_us-gaap_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-01-02_custom_VicisCapitalAgreementAmdtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">OPRX:VicisCapitalAgreementAmdtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-01-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_custom_VicisCapitalAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">OPRX:VicisCapitalAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-03-17_custom_SecuritiesSoldUnderAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">OPRX:SecuritiesSoldUnderAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-03-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-03-16to2014-03-18_custom_SecuritiesSoldUnderAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">OPRX:SecuritiesSoldUnderAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-03-16</xbrli:startDate>
        <xbrli:endDate>2014-03-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-02-28to2014-03-18_custom_LDMSettlementAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">OPRX:LDMSettlementAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-02-28</xbrli:startDate>
        <xbrli:endDate>2014-03-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Percent">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="From2013-01-01to2013-12-31">OptimizeRx Corp</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2013-01-01to2013-12-31">0001448431</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2013-01-01to2013-12-31">S-1</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2013-01-01to2013-12-31">2013-12-31</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2013-01-01to2013-12-31">false</dei:AmendmentFlag>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2013-01-01to2013-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2013-01-01to2013-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2013-01-01to2013-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2013-01-01to2013-12-31">Smaller Reporting Company</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2013-01-01to2013-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2013-01-01to2013-12-31">2013</dei:DocumentFiscalYearFocus>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1118243</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">284263</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1566964</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">616798</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">11771</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">68158</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">2696978</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">969219</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">15057</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">20685</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">885950</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">793236</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:CapitalizedComputerSoftwareNet contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">404986</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:CapitalizedComputerSoftwareNet contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">387215</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:SecurityDeposit contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">5049</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">5049</us-gaap:SecurityDeposit>
    <us-gaap:OtherAssets contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1295985</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">1185500</us-gaap:OtherAssets>
    <us-gaap:Assets contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">4008020</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">2175404</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">188739</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">54693</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">570000</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">570000</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">12000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">6000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1968652</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">770522</us-gaap:LiabilitiesCurrent>
    <us-gaap:CommonStockValue contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">14773</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">14232</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2013-09-20_custom_SeparationAgreementMember" unitRef="USD" decimals="0">505000</us-gaap:CommonStockValue>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">18148049</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">20058051</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">8726708</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">6164666</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">-24616220</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">-24832067</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">4008020</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">2175404</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:DeferredCompensationEquity contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">233942</us-gaap:DeferredCompensationEquity>
    <us-gaap:DeferredCompensationEquity contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">0</us-gaap:DeferredCompensationEquity>
    <us-gaap:DeferredCompensationEquity contextRef="AsOf2013-09-20_custom_SeparationAgreementMember" unitRef="USD" decimals="0">174808</us-gaap:DeferredCompensationEquity>
    <us-gaap:DeferredCompensationEquity contextRef="AsOf2013-11-08_custom_TwoNonEmployeeStockOptionsMember" unitRef="USD" decimals="0">-59134</us-gaap:DeferredCompensationEquity>
    <us-gaap:NetIncomeLoss contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">215847</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-454553</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2012-01-01to2012-12-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">-454553</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2013-01-01to2013-12-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">215847</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2012-01-01to2013-12-31_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">-363976</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">193971</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">187104</us-gaap:DepreciationAndAmortization>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-950166</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-151851</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">56387</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">50874</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">134046</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-282019</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">6000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-66000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-45000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-281353</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1132628</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-624033</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">2230</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-298684</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-50870</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">833980</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-674903</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:InterestPaid contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">0</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">0</us-gaap:InterestPaid>
    <us-gaap:IncomeTaxesPaid contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxesPaid>
    <OPRX:WebsiteDevelopmentCosts contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-148060</OPRX:WebsiteDevelopmentCosts>
    <OPRX:WebsiteDevelopmentCosts contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-48640</OPRX:WebsiteDevelopmentCosts>
    <OPRX:PatentRights contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-150588</OPRX:PatentRights>
    <OPRX:PatentRights contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">0</OPRX:PatentRights>
    <OPRX:OfficerCompensationSettlementOfSeverance contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">233942</OPRX:OfficerCompensationSettlementOfSeverance>
    <OPRX:OfficerCompensationSettlementOfSeverance contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">0</OPRX:OfficerCompensationSettlementOfSeverance>
    <us-gaap:Cash contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1118243</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">284263</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">959166</us-gaap:Cash>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2013-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2012-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">14773496</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">14232496</us-gaap:CommonStockSharesIssued>
    <us-gaap:ShareBasedCompensation contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">411412</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">285605</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2011-01-01to2011-12-31_ThreeEmployeesStockOptionsMember" unitRef="USD" decimals="0">187005</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2012-01-01to2012-05-30_ThreeEmployeesStockOptionsMember" unitRef="USD" decimals="0">133580</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2011-01-01to2011-12-31_TwoEmployeesStockOptionsMember" unitRef="USD" decimals="0">2480</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2011-01-01to2011-12-31_IndividualStockOptionsMember" unitRef="USD" decimals="0">8346</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2012-01-01to2012-06-30_FourNonEmployeesStockOptionsMember" unitRef="USD" decimals="0">35091</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2012-01-01to2012-12-31_NonEmployeeStockOptionsMember" unitRef="USD" decimals="0">8335</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2012-01-01to2012-12-31_TwoEmployeesStockOptionsMember" unitRef="USD" decimals="0">16790</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2012-01-01to2012-12-31_IndividualStockOptionsMember" unitRef="USD" decimals="0">91811</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2013-01-01to2013-12-31_NonEmployeeStockOptionsMember" unitRef="USD" decimals="0">31672</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2013-01-01to2013-12-31_custom_SixEmployeesStockOptionsMember" unitRef="USD" decimals="0">7720</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2013-10-01to2013-12-31_custom_TwoNonEmployeeStockOptionsMember" unitRef="USD" decimals="0">11827</us-gaap:ShareBasedCompensation>
    <us-gaap:NatureOfOperations contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Optimizer Systems, LLC was formed in the State&#13;of Michigan on January 31, 2006. It then became a corporation in the State of Michigan on October 22, 2007 and changed its name&#13;to OptimizeRx Corporation. On April 14, 2008, RFID, Ltd., a Colorado corporation, consummated a reverse merger by entering into&#13;a share exchange agreement with the stockholders of OptimizeRx Corporation, pursuant to which the stockholders of OptimizeRx Corporation&#13;exchanged all of the issued and outstanding capital stock of OptimizeRx Corporation for 1,256,958 shares of common stock of RFID,&#13;Ltd., representing 100% of the outstanding capital stock of RFID, Ltd. As of April&amp;#160;30, 2008, RFID&amp;#146;s officers and directors&#13;resigned their positions and RFID changed its business to OptimizeRx&amp;#146;s business. On April&amp;#160;15, 2008, RFID, Ltd.&amp;#146;s&#13;corporate name was changed to OptimizeRx Corporation. On September&amp;#160;4, 2008, a migratory merger was completed, thereby changing&#13;the state of incorporation from Colorado to Nevada, resulting in the current corporate structure, in which OptimizeRx Corporation,&#13;a Nevada corporation, is the parent corporation, and OptimizeRx Corporation, a Michigan corporation, is a wholly-owned subsidiary&#13;(together, "OptimizeRx" and "the Company").&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The wholly-owned subsidiary, OptimizeRx Corporation,&#13;is a technology solutions company targeting the health care industry. Their objective is to bring better access to better care&#13;through connecting patients, physicians and pharmaceutical manufacturers through technology. Once defined as a marketing and advertising&#13;company through its consumer website, OptimizeRx is maturing as a technology solutions provider as it launched its direct to physician&#13;solution, SampleMD. SampleMD allows physicians to search, print and send available sample trial vouchers and/or co-pay coupons&#13;on behalf of their patients. The SampleMD solution can either sit on the doctor&amp;#146;s desktop or can be integrated into the ePrescribing&#13;or Electronic Medical Records applications. OptimizeRx solutions provide pharmaceutical manufacturers either a direct to consumer&#13;and/or direct to physician channels for communicating and promoting their products. It provides health care providers a means to&#13;provide sampling and coupons without having to physically store samples on site, and it provides better access and affordability&#13;to the patients.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <OPRX:CapitalStockOfOptimizerxCorporationExchangedForCommonStockOfRFID contextRef="AsOf2008-04-18" unitRef="Shares" decimals="INF">1256958</OPRX:CapitalStockOfOptimizerxCorporationExchangedForCommonStockOfRFID>
    <OPRX:Ownership contextRef="AsOf2008-04-18" unitRef="Percent" decimals="INF">1.00</OPRX:Ownership>
    <OPRX:EntityIncorporationDateOfOrganization contextRef="From2013-01-01to2013-12-31">2006-01-31</OPRX:EntityIncorporationDateOfOrganization>
    <dei:EntityIncorporationDateOfIncorporation contextRef="From2013-01-01to2013-12-31">2007-10-22</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="text-align: justify; font: 11pt Times New Roman, Times, Serif; margin: 0px"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Basis of Presentation&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The financial statements of the Company have&#13;been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in&#13;US dollars.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Accounting Basis&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company uses the accrual basis of accounting&#13;and accounting principles generally accepted in the United States of America (&amp;#147;GAAP&amp;#148; accounting). The Company has adopted&#13;a December 31 fiscal year end.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;&lt;u&gt;Principles of Consolidation&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;The financial statements&#13;reflect the consolidated results of OptimizeRx Corporation (a Nevada corporation) and its wholly owned subsidiary OptimizeRx Corporation&#13;(a Michigan corporation). All material inter-company transactions have been eliminated in the consolidation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;&lt;u&gt;Cash and Cash Equivalents&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;For purposes of the&#13;accompanying financial statements, the Company considers all highly liquid instruments with an initial maturity of three months&#13;or less to be cash equivalents.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Fair Value of Financial Instruments&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;The fair value of cash,&#13;accounts receivable, prepaid expenses, patent rights, web development costs, accounts payable, accounts payable &amp;#150; related&#13;party, accrued expenses and deferred revenue approximates the carrying amount of these financial instruments due to their short-term&#13;nature. The fair value of long-term debt, which approximates its carrying value, is based on current rates at which the Company&#13;could borrow funds with similar remaining maturities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Fair value is defined as the price that would&#13;be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at&#13;the measurement date and in the principal or most advantageous market for that asset or liability. The fair value should be calculated&#13;based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity.&#13;In addition, the fair value of liabilities should include consideration of non-performance risk including our own credit risk.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition to defining fair value, the disclosure&#13;requirements around fair value establish a fair value hierarchy for valuation inputs which is expanded. The hierarchy prioritizes&#13;the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each&#13;fair value measurement is reported in one of the three levels which is determined by the lowest level input that is significant&#13;to the fair value measurement in its entirety. These levels are:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 &amp;#150; inputs are based upon unadjusted&#13;quoted prices for identical instruments traded in active markets.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 &amp;#150; inputs are based upon significant&#13;observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets&#13;that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or&#13;can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 &amp;#150; inputs are generally unobservable&#13;and typically reflect management&amp;#146;s estimates of assumptions that market participants would use in pricing the asset or liability.&#13;The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow&#13;models, and similar techniques. The Company&amp;#146;s stock options and warrants are valued using level 3 inputs.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The carrying value of the Company&amp;#146;s financial&#13;assets and liabilities which consist of cash, accounts receivable, prepaid expenses, patent rights, web development costs, accounts&#13;payable, accounts payable &amp;#150; related party, accrued expenses and deferred revenue are valued using level 1 inputs. The Company&#13;believes that the recorded values approximate their fair value due to the short maturity of such instruments. Unless otherwise&#13;noted, it is management&amp;#146;s opinion that the Company is not exposed to significant interest, exchange or credit risks arising&#13;from these financial instruments.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Accounts Receivable and Allowance for Doubtful&#13;Accounts&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounts receivable are reported at realizable&#13;value, net of allowances for doubtful accounts, which is estimated and recorded in the period the related revenue is recorded.&#13;The Company has a standardized approach to estimate and review the collectability of its receivables based on a number of factors,&#13;including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of&#13;the estimation process related to allowances for doubtful accounts. In addition, the Company regularly assesses the state of its&#13;billing operations in order to identify issues, which may impact the collectability of these receivables or reserve estimates.&#13;Bad debt expense was $0 and $6,923 for the years ended December&amp;#160;31, 2013 and 2012, respectively. The allowance for doubtful&#13;accounts was $0 as of December&amp;#160;31, 2013 and 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Property and Equipment&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;The capital assets&#13;are being depreciated over their estimated useful lives, three to seven years using the straight-line method of depreciation for&#13;book purposes.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Revenue Recognition and Revenue Share Expense&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All revenue is recognized when it is earned.&#13;Revenues are generated either through the Company&amp;#146;s web-based activities, in which we earn revenue from advertising and lead&#13;generation activities, from our SampleMD activities by which we deliver eCoupons and eVouchers through a distribution network of&#13;ePrescribers and Electronic Health Record technology providers (channel partners), or from reselling services for other of our&#13;partners products that complement our business.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For our SampleMD business the company recognizes&#13;setup fees that are required for integrating client offerings and campaigns into the SampleMD content delivery system and network.&#13;Setup fees are recognized upon completion of the setup and launch of the client&amp;#146;s campaign within the SampleMD system. As&#13;the eCoupons and or eVouchers are distributed through the SampleMD platform and network of channel partners (a transaction), these&#13;transactions are recorded and revenue is recognized. Revenue for transactions can be realized as cost per distribution or cost&#13;per redemption depending on the client contract. Additionally, the company also recognizes revenue for providing program performance&#13;reporting and maintenance, either by the company directly delivering reports or by providing access to its online reporting portal&#13;that the client can utilize. These fees are administered monthly and recognized as recurring monthly revenue.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The company on occasion has also resold products&#13;and or services that are available through our channel partners, and that is complementary to our core businesses and client base.&#13;In these events net revenue is recognized as this is a commission based revenue split that the company recognizes.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Based on the volume of transactions that are&#13;delivered through our channel partner network, we provide a revenue share to compensate the partner for their promotion of the&#13;campaign. Revenue shares are a negotiated percentage of the transaction fee depending upon if the revenue is generated through&#13;distributions and or redemptions and can also be specific to special considerations and campaigns. Traditionally, revenue share&#13;has been recognized between 25% and 50% of the transaction value. See Note 18.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Income Taxes&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Income taxes are computed using the asset and&#13;liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the&#13;differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted&#13;tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence,&#13;are not expected to be realized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Use of Estimates&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;The preparation of&#13;financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions&#13;that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of&#13;revenues and expenses during the reporting period. Estimates and assumptions have been made in determining the depreciable lives&#13;of such assets and the allowance for doubtful accounts receivable. Actual results could differ from these estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Concentration of Credit Risks&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;The Company maintains&#13;its cash and cash equivalents in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not&#13;experienced any losses in such accounts; however, amounts in excess of the federally insured limit may be at risk if the bank experiences&#13;financial difficulties.&lt;/p&gt;&#13;&#13;&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Research and Development&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;The Company&amp;#146;s&#13;key members are part of a continual research development team and monitor new technologies, trends, services and partnerships that&#13;can provide the Company with additional services, value to healthcare and pharmaceutical industries and to the patients it serves.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.25in 0 0; letter-spacing: -0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;The Company seeks to&#13;educate team members through understanding of all market dynamics that have the potential to affect the business both short term&#13;and longer term. The primary goal is to help patients better afford and access the medicines their doctor prescribes, as well as&#13;other healthcare products and services they need. Based on this, the Company continually seeks better ways to meet this mission&#13;through technology, better user experiences and new ways to engage industries to provide new support for patients needing their&#13;products. The Company is always seeking new services and solutions to offer. At this time, the three current platforms provide&#13;robust opportunities and growth during the next five years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Earnings Per Common and Common Equivalent&#13;Share&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;The computation of&#13;basic earnings per common share is computed using the weighted average number of common shares outstanding during the year. The&#13;computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the year&#13;plus common stock equivalents which would arise from the exercise of warrants outstanding using the treasury stock method and the&#13;average market price per share during the year. Options, warrants and convertible preferred stock which are common stock equivalents&#13;are included in the diluted earnings per share calculation for the year ended December&amp;#160;31, 2013. They have not been included&#13;in the diluted earnings per share calculation for the year ended December&amp;#160;31, 2012 since their effect is anti-dilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Impairment of Long-Lived Assets&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;The Company continually&#13;monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable.&#13;When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining&#13;whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the&#13;future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess&#13;of the carrying amount over the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount&#13;or the fair value less costs to sell.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Recently Issued Accounting Guidance&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;The Company does not&#13;expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company&amp;#146;s results of&#13;operations, financial position or cash flow.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The financial statements of the Company have been prepared in accordance with&#13;generally accepted accounting principles in the United States of America and are presented in US dollars.&lt;/p&gt;&#13;&#13;&lt;p&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <OPRX:SignificantAccountingPolicyPoliciesTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company uses the accrual basis of accounting and accounting principles generally accepted in the United States of America (&amp;#147;GAAP&amp;#148;&#13;accounting). The Company has adopted a December 31 fiscal year end.&lt;/font&gt;&lt;/p&gt;</OPRX:SignificantAccountingPolicyPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;The financial statements&#13;reflect the consolidated results of OptimizeRx Corporation (a Nevada corporation) and its wholly owned subsidiary OptimizeRx Corporation&#13;(a Michigan corporation). All material inter-company transactions have been eliminated in the consolidation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;For purposes of the accompanying financial statements, the Company considers&#13;all highly liquid instruments with an initial maturity of three months or less to be cash equivalents.&lt;/p&gt;&#13;&#13;&lt;p&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;The fair value of cash,&#13;accounts receivable, prepaid expenses, patent rights, web development costs, accounts payable, accounts payable &amp;#150; related&#13;party, accrued expenses and deferred revenue approximates the carrying amount of these financial instruments due to their short-term&#13;nature. The fair value of long-term debt, which approximates its carrying value, is based on current rates at which the Company&#13;could borrow funds with similar remaining maturities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Fair value is defined as the price that would&#13;be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at&#13;the measurement date and in the principal or most advantageous market for that asset or liability. The fair value should be calculated&#13;based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity.&#13;In addition, the fair value of liabilities should include consideration of non-performance risk including our own credit risk.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition to defining fair value, the disclosure&#13;requirements around fair value establish a fair value hierarchy for valuation inputs which is expanded. The hierarchy prioritizes&#13;the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each&#13;fair value measurement is reported in one of the three levels which is determined by the lowest level input that is significant&#13;to the fair value measurement in its entirety. These levels are:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 &amp;#150; inputs are based upon unadjusted&#13;quoted prices for identical instruments traded in active markets.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 &amp;#150; inputs are based upon significant&#13;observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets&#13;that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or&#13;can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 &amp;#150; inputs are generally unobservable&#13;and typically reflect management&amp;#146;s estimates of assumptions that market participants would use in pricing the asset or liability.&#13;The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow&#13;models, and similar techniques. The Company&amp;#146;s stock options and warrants are valued using level 3 inputs.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The carrying value of the Company&amp;#146;s financial&#13;assets and liabilities which consist of cash, accounts receivable, prepaid expenses, patent rights, web development costs, accounts&#13;payable, accounts payable &amp;#150; related party, accrued expenses and deferred revenue are valued using level 1 inputs. The Company&#13;believes that the recorded values approximate their fair value due to the short maturity of such instruments. Unless otherwise&#13;noted, it is management&amp;#146;s opinion that the Company is not exposed to significant interest, exchange or credit risks arising&#13;from these financial instruments.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PremiumsReceivableAllowanceForDoubtfulAccountsEstimationMethodologyPolicy contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounts receivable are reported at realizable&#13;value, net of allowances for doubtful accounts, which is estimated and recorded in the period the related revenue is recorded.&#13;The Company has a standardized approach to estimate and review the collectability of its receivables based on a number of factors,&#13;including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of&#13;the estimation process related to allowances for doubtful accounts. In addition, the Company regularly assesses the state of its&#13;billing operations in order to identify issues, which may impact the collectability of these receivables or reserve estimates.&#13;Bad debt expense was $0 and $6,923 for the years ended December&amp;#160;31, 2013 and 2012, respectively. The allowance for doubtful&#13;accounts was $0 as of December&amp;#160;31, 2013 and 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:PremiumsReceivableAllowanceForDoubtfulAccountsEstimationMethodologyPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The capital assets are being depreciated over their estimated useful lives,&#13;three to seven years using the straight-line method of depreciation for book purposes.&lt;/p&gt;&#13;&#13;&lt;p&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All revenue is recognized when it is earned.&#13;Revenues are generated either through the Company&amp;#146;s web-based activities, in which we earn revenue from advertising and lead&#13;generation activities, from our SampleMD activities by which we deliver eCoupons and eVouchers through a distribution network of&#13;ePrescribers and Electronic Health Record technology providers (channel partners), or from reselling services for other of our&#13;partners products that complement our business.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For our SampleMD business the company recognizes&#13;setup fees that are required for integrating client offerings and campaigns into the SampleMD content delivery system and network.&#13;Setup fees are recognized upon completion of the setup and launch of the client&amp;#146;s campaign within the SampleMD system. As&#13;the eCoupons and or eVouchers are distributed through the SampleMD platform and network of channel partners (a transaction), these&#13;transactions are recorded and revenue is recognized. Revenue for transactions can be realized as cost per distribution or cost&#13;per redemption depending on the client contract. Additionally, the company also recognizes revenue for providing program performance&#13;reporting and maintenance, either by the company directly delivering reports or by providing access to its online reporting portal&#13;that the client can utilize. These fees are administered monthly and recognized as recurring monthly revenue.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The company on occasion has also resold products&#13;and or services that are available through our channel partners, and that is complementary to our core businesses and client base.&#13;In these events net revenue is recognized as this is a commission based revenue split that the company recognizes.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Based on the volume of transactions that are&#13;delivered through our channel partner network, we provide a revenue share to compensate the partner for their promotion of the&#13;campaign. Revenue shares are a negotiated percentage of the transaction fee depending upon if the revenue is generated through&#13;distributions and or redemptions and can also be specific to special considerations and campaigns. Traditionally, revenue share&#13;has been recognized between 25% and 50% of the transaction value. See Note 18.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Income taxes are computed using the asset and liability method. Under the asset&#13;and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial&#13;reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation&#13;allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.&lt;/p&gt;&#13;&#13;&lt;p&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company maintains its cash and cash equivalents in bank deposit accounts,&#13;which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts; however, amounts&#13;in excess of the federally insured limit may be at risk if the bank experiences financial difficulties.&lt;/p&gt;&#13;&#13;&lt;p&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;The computation of&#13;basic earnings per common share is computed using the weighted average number of common shares outstanding during the year. The&#13;computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the year&#13;plus common stock equivalents which would arise from the exercise of warrants outstanding using the treasury stock method and the&#13;average market price per share during the year. Options, warrants and convertible preferred stock which are common stock equivalents&#13;are included in the diluted earnings per share calculation for the year ended December&amp;#160;31, 2013. They have not been included&#13;in the diluted earnings per share calculation for the year ended December&amp;#160;31, 2012 since their effect is anti-dilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0px"&gt;The&#13;Company continually monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may&#13;not be recoverable. When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived&#13;assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows.&#13;If the total of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss&#13;based on the excess of the carrying amount over the fair value of the assets. Assets to be disposed of are reported at the lower&#13;of the carrying amount or the fair value less costs to sell.&lt;/font&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company does not expect the adoption of recently issued accounting pronouncements&#13;to have a significant impact on the Company&amp;#146;s results of operations, financial position or cash flow.&lt;/p&gt;&#13;&#13;&lt;p&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <dei:CurrentFiscalYearEndDate contextRef="From2013-01-01to2013-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <OPRX:CapitalAssetsUsefulLifeMinimum contextRef="From2013-01-01to2013-12-31">P3Y</OPRX:CapitalAssetsUsefulLifeMinimum>
    <OPRX:CapitalAssetsUsefulLifeMaximum contextRef="From2013-01-01to2013-12-31">P7Y</OPRX:CapitalAssetsUsefulLifeMaximum>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;Prepaid expenses consisted&#13;of the following as of December&amp;#160;31, 2013 and 2012:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 40%; border-collapse: collapse; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="width: 54%; padding-left: 5.4pt"&gt;Insurance&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;6,722&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;6,437&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Rent&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5,049&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5,049&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Consulting&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;31,672&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 5.4pt"&gt;Legal&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;25,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 5.4pt"&gt;Total prepaid expenses&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;11,771&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;68,158&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;&lt;/p&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <OPRX:ScheduleOfPrepaidExpensesTableTextBlock contextRef="From2013-01-01to2013-12-31">&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 40%; border-collapse: collapse; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="width: 54%; padding-left: 5.4pt"&gt;Insurance&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;6,722&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;6,437&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Rent&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5,049&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5,049&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Consulting&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;31,672&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 5.4pt"&gt;Legal&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;25,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 5.4pt"&gt;Total prepaid expenses&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;11,771&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;68,158&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</OPRX:ScheduleOfPrepaidExpensesTableTextBlock>
    <OPRX:Insurance contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">6722</OPRX:Insurance>
    <OPRX:Insurance contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">6437</OPRX:Insurance>
    <OPRX:Rent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">5049</OPRX:Rent>
    <OPRX:Rent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">5049</OPRX:Rent>
    <OPRX:ConsultingExpense contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">0</OPRX:ConsultingExpense>
    <OPRX:ConsultingExpense contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">31672</OPRX:ConsultingExpense>
    <OPRX:LegalCosts contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">0</OPRX:LegalCosts>
    <OPRX:LegalCosts contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">25000</OPRX:LegalCosts>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="text-align: justify; font: 11pt Times New Roman, Times, Serif; margin: 0px; letter-spacing: -0.1pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company owned equipment recorded at cost&#13;which consisted of the following as of December&amp;#160;31, 2013 and 2012:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 40%; border-collapse: collapse; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="width: 54%; text-align: left; padding-left: 5.4pt"&gt;Computer equipment&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;22,360&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;22,360&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 5.4pt"&gt;Furniture and fixtures&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;11,088&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;11,088&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Subtotal&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;33,448&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;33,448&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 5.4pt"&gt;Accumulated depreciation&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(18,391&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(12,763&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Property and equipment, net&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;15,057&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;20,685&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Depreciation expense was $5,628 and $5,476&#13;for the years ended December&amp;#160;31, 2013 and 2012, respectively.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="text-align: justify; font: 11pt Times New Roman, Times, Serif; margin: 0px; letter-spacing: -0.1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <OPRX:ScheduleOfPropertyEquipmentTextBlockTableTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 40%; border-collapse: collapse; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="width: 54%; text-align: left; padding-left: 5.4pt"&gt;Computer equipment&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;22,360&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;22,360&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 5.4pt"&gt;Furniture and fixtures&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;11,088&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;11,088&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Subtotal&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;33,448&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;33,448&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 5.4pt"&gt;Accumulated depreciation&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(18,391&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(12,763&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Property and equipment, net&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;15,057&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;20,685&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</OPRX:ScheduleOfPropertyEquipmentTextBlockTableTextBlock>
    <OPRX:ComputerEquipmentGross contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">22360</OPRX:ComputerEquipmentGross>
    <OPRX:ComputerEquipmentGross contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">22360</OPRX:ComputerEquipmentGross>
    <us-gaap:FurnitureAndFixturesGross contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">11088</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">11088</us-gaap:FurnitureAndFixturesGross>
    <OPRX:SubtotalOfPropertyEquipmentCost contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">33448</OPRX:SubtotalOfPropertyEquipmentCost>
    <OPRX:SubtotalOfPropertyEquipmentCost contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">33448</OPRX:SubtotalOfPropertyEquipmentCost>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">18391</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">12763</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">5628</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">5476</us-gaap:Depreciation>
    <OPRX:WebsiteDevelopmentTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has capitalized costs in developing&#13;their web-based technology, which consisted of the following as of December&amp;#160;31, 2013 and 2012:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 45%; border-collapse: collapse; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="width: 54%; text-align: left; padding-left: 5.4pt"&gt;OptimizeRx web-based technology&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;154,133&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;154,133&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;SampleMD web-based technology&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;602,517&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;602,517&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 5.4pt"&gt;SampleMD 2.0 web-based technology&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;148,060&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Subtotal, web-based technology&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;904,710&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;756,650&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Accumulated amortization&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(440,641&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(310,352&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 5.4pt"&gt;Impairment&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(59,083&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(59,083&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Web-based technology, net&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;404,986&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;387,215&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Amortization is recorded using the straight-line&#13;method over a period of five years. The Company is currently developing enhanced SampleMD web-based technology and has capitalized&#13;$148,060. The development is currently in process. It was not completed at December&amp;#160;31, 2013. Accordingly, no amortization&#13;has been recorded. The development is expected to be completed in 2014. Amortization expense for the web-based technology costs&#13;was $130,289 and $126,923 for the years ended December&amp;#160;31, 2013 and 2012, respectively.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</OPRX:WebsiteDevelopmentTextBlock>
    <OPRX:ScheduleOfWebsiteDevelopmentCostsTableTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 45%; border-collapse: collapse; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="width: 54%; text-align: left; padding-left: 5.4pt"&gt;OptimizeRx web-based technology&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;154,133&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;154,133&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;SampleMD web-based technology&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;602,517&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;602,517&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 5.4pt"&gt;SampleMD 2.0 web-based technology&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;148,060&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Subtotal, web-based technology&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;904,710&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;756,650&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Accumulated amortization&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(440,641&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(310,352&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 5.4pt"&gt;Impairment&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(59,083&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(59,083&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Web-based technology, net&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;404,986&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;387,215&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</OPRX:ScheduleOfWebsiteDevelopmentCostsTableTextBlock>
    <OPRX:WebsiteDevelopmentCost1 contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">154133</OPRX:WebsiteDevelopmentCost1>
    <OPRX:WebsiteDevelopmentCost1 contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">154133</OPRX:WebsiteDevelopmentCost1>
    <OPRX:WebsiteDevelopmentCost2 contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">602517</OPRX:WebsiteDevelopmentCost2>
    <OPRX:WebsiteDevelopmentCost2 contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">602517</OPRX:WebsiteDevelopmentCost2>
    <OPRX:SubtotalofWebsiteDevelopmentCosts contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">904710</OPRX:SubtotalofWebsiteDevelopmentCosts>
    <OPRX:SubtotalofWebsiteDevelopmentCosts contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">756650</OPRX:SubtotalofWebsiteDevelopmentCosts>
    <us-gaap:AccumulatedAmortizationOfOtherDeferredCosts contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">440641</us-gaap:AccumulatedAmortizationOfOtherDeferredCosts>
    <us-gaap:AccumulatedAmortizationOfOtherDeferredCosts contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">310352</us-gaap:AccumulatedAmortizationOfOtherDeferredCosts>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">-59083</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">-59083</us-gaap:UnamortizedDebtIssuanceExpense>
    <OPRX:WebsiteDevelopmentCost3 contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">148060</OPRX:WebsiteDevelopmentCost3>
    <OPRX:WebsiteDevelopmentCost3 contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">0</OPRX:WebsiteDevelopmentCost3>
    <OPRX:UsefulLifeOfWebsite contextRef="From2013-01-01to2013-12-31">P5Y</OPRX:UsefulLifeOfWebsite>
    <OPRX:AmortizationExpenseOfWebsite contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">130289</OPRX:AmortizationExpenseOfWebsite>
    <OPRX:AmortizationExpenseOfWebsite contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">126923</OPRX:AmortizationExpenseOfWebsite>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April&amp;#160;26, 2010, the Company acquired&#13;from an officer and shareholder the technical contributions and assignment of all exclusive rights to and for the SampleMD patent&#13;in exchange for 300,000 shares of common stock to be granted at the discretion of the seller in addition to 200,000 stock options&#13;valued at $360,000. The shares were valued on the grant date at $570,000 and have been recorded as a payable to the related party.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has capitalized costs in purchasing&#13;and defending the SampleMD patent, which consisted of the following as of December&amp;#160;31, 2013 and 2012:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/6pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 45%; border-collapse: collapse; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="width: 54%; text-align: left; padding-left: 5.4pt"&gt;Patent rights and intangible assets&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;930,000&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;930,000&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Patent defense costs&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;87,993&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;New patents and trademarks&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;62,595&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 5.4pt"&gt;Accumulated amortization&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(194,638&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(136,764&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Patent rights and intangible assets, net&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;885,950&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;793,236&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company began amortizing the patent, using&#13;the straight-line method over the estimated useful life of 17 years, once it was put into service in July 2010. In 2013, the Company&#13;began incurring costs related to defense of the patent. These costs have been capitalized and will be amortized using the straight-line&#13;method over the remaining useful life of the original patent. Amortization expense was $57,874 and $54,705 for the years ended&#13;December&amp;#160;31, 2013 and 2012, respectively.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 11pt/6pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 45%; border-collapse: collapse; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="width: 54%; text-align: left; padding-left: 5.4pt"&gt;Patent rights and intangible assets&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;930,000&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;930,000&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Patent defense costs&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;87,993&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;New patents and trademarks&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;62,595&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 5.4pt"&gt;Accumulated amortization&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(194,638&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(136,764&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Patent rights and intangible assets, net&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;885,950&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;793,236&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <OPRX:AccumulatedAmortizationOfPatentRights contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">194638</OPRX:AccumulatedAmortizationOfPatentRights>
    <OPRX:AccumulatedAmortizationOfPatentRights contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">136764</OPRX:AccumulatedAmortizationOfPatentRights>
    <OPRX:PatentsDefenseCost contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">87993</OPRX:PatentsDefenseCost>
    <OPRX:PatentsDefenseCost contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">0</OPRX:PatentsDefenseCost>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">930000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">930000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <OPRX:CommonStockSharesGrantedToAcquireExclusivePatentRights contextRef="AsOf2010-04-26" unitRef="Shares" decimals="INF">300000</OPRX:CommonStockSharesGrantedToAcquireExclusivePatentRights>
    <OPRX:CommonStockSharesGrantedToAcquireExclusivePatentRights contextRef="AsOf2010-12-31" unitRef="Shares" decimals="INF">300000</OPRX:CommonStockSharesGrantedToAcquireExclusivePatentRights>
    <OPRX:OptionsGrantedToAcquireExclusivePatentRights contextRef="AsOf2010-04-26" unitRef="Shares" decimals="INF">200000</OPRX:OptionsGrantedToAcquireExclusivePatentRights>
    <OPRX:OptionsGrantedToAcquireExclusivePatentRights contextRef="AsOf2010-12-31" unitRef="Shares" decimals="INF">200000</OPRX:OptionsGrantedToAcquireExclusivePatentRights>
    <OPRX:OptionsGrantedToAcquireExclusivePatentRightsValue contextRef="AsOf2010-04-26" unitRef="USD" decimals="0">360000</OPRX:OptionsGrantedToAcquireExclusivePatentRightsValue>
    <OPRX:OptionsGrantedToAcquireExclusivePatentRightsValue contextRef="AsOf2010-12-31" unitRef="USD" decimals="0">360000</OPRX:OptionsGrantedToAcquireExclusivePatentRightsValue>
    <OPRX:CommonStockSharesGrantedToAcquireExclusivePatentRightsValue contextRef="AsOf2010-04-26" unitRef="USD" decimals="0">570000</OPRX:CommonStockSharesGrantedToAcquireExclusivePatentRightsValue>
    <OPRX:CommonStockSharesGrantedToAcquireExclusivePatentRightsValue contextRef="AsOf2010-12-31" unitRef="USD" decimals="0">570000</OPRX:CommonStockSharesGrantedToAcquireExclusivePatentRightsValue>
    <OPRX:UsefulLifeOfPatent contextRef="From2013-01-01to2013-12-31">P17Y</OPRX:UsefulLifeOfPatent>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">57874</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">54705</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accrued&#13;expenses at December 31, 2013 and 2012 consisted of amounts owed to the Company&amp;#146;s outside independent auditors for services&#13;rendered for periods reported on in these financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p&gt;&lt;/p&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:DeferredRevenueDisclosureTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="margin: 0pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company has signed several contracts with customers&#13;for either the distribution or redemption of coupons. The payments are not taken into revenue until either the coupon is distributed&#13;to a patient or the coupon has been redeemed depending on the specific contract. The distributions and redemptions are tracked&#13;by the Company&amp;#146;s administrative tool. Additionally, customer setup contracts that have been paid in full are deferred until&#13;the Company has completed the obligations of the contacts. Deferred revenue was $4,252 and $49,252 as of December&amp;#160;31, 2013&#13;and 2012, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p&gt;&lt;/p&gt;</us-gaap:DeferredRevenueDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="margin: 0pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During the year ended December&amp;#160;31, 2010, the&#13;Company acquired from an officer and shareholder the technical contributions and assignment of all exclusive rights to and for&#13;the SampleMD patent currently in process in exchange for 300,000 shares of common stock to be granted at the discretion of the&#13;seller in addition to 200,000 stock options valued at $360,000. The shares were valued on the grant date at $570,000 and have&#13;been recorded as a payable to the related party.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;OptimizeRx Corporation has 500,000,000 shares&#13;of $.001 par value common stock authorized as of December 31, 2013. There were 14,773,496 and 14,232,496 common shares issued and&#13;outstanding at December&amp;#160;31, 2013 and 2012, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June&amp;#160;1, 2012, the Company entered into&#13;a consulting agreement with North Coast Advisors, Inc. for various services. The Company agreed to issue 40,000 shares of common&#13;stock as of the date of the contract. However, these shares were not issued until July&amp;#160;12, 2012. The Company also agreed to&#13;issue an additional 40,000 shares every six months in alignment with the agreement renewal up to the two years of the agreement.&#13;The first 40,000 shares were valued at the Company&amp;#146;s common stock price as of the date of the contract, which was $1.12/share&#13;and has been expensed. No additional shares were issued and the agreement was voided and replaced by a new agreement as noted below.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June&amp;#160;1, 2013, the Company entered into&#13;a consulting agreement with North Coast Advisors, Inc. for various services. The Company agreed to issue 20,000 shares of common&#13;stock as of the date of the contract. The Company also agreed to issue an additional 20,000 shares every six months in alignment&#13;with the agreement renewal up to the two years of the agreement. The first 20,000 shares were valued at the Company&amp;#146;s common&#13;stock closing price as of the date of the contract, which was $1.945/share; and the second 20,000 shares were valued at the Company&amp;#146;s&#13;common stock closing price of $1.50/share on the date of issuance, and have been expensed.&lt;/p&gt;&#13;&#13;&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September&amp;#160;20, 2013, the Company entered&#13;into a separation agreement that includes post-employment consulting services with a former officer. The Company agreed to issue&#13;500,000 shares of common stock, 250,000 shares immediately and 250,000 by January&amp;#160;1, 2014. The first 250,000 shares have been&#13;issued and the Company has recognized the entire issuance in the December 31, 2013 shares outstanding. The shares were valued at&#13;$505,000 and $174,808 of that amount remains as deferred stock compensation as of December&amp;#160;31, 2013.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SharesIssued contextRef="AsOf2013-06-01_custom_NorthCoastAdvisorsMember" unitRef="Shares" decimals="INF">20000</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2012-07-12_custom_NorthCoastAdvisorsMember" unitRef="Shares" decimals="INF">40000</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2013-09-20_custom_SeparationAgreementMember" unitRef="Shares" decimals="INF">250000</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2014-01-02_custom_SeparationAgreementMember" unitRef="Shares" decimals="INF">250000</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2013-12-01_custom_NorthCoastAdvisorsMember" unitRef="Shares" decimals="INF">20000</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2011-12-31_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">65</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2012-12-31_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">65</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2013-12-31_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">65</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2011-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">14192496</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2012-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">14232496</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">14773496</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2014-03-17_custom_SecuritiesSoldUnderAgreementsMember" unitRef="Shares" decimals="INF">8333333</us-gaap:SharesIssued>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2013-06-01_custom_NorthCoastAdvisorsMember" unitRef="USDPShares" decimals="INF">1.945</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2012-07-12_custom_NorthCoastAdvisorsMember" unitRef="USDPShares" decimals="INF">1.12</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2013-12-01_custom_NorthCoastAdvisorsMember" unitRef="USDPShares" decimals="INF">1.50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2014-03-17_custom_SecuritiesSoldUnderAgreementsMember" unitRef="USDPShares" decimals="INF">1.20</us-gaap:SharesIssuedPricePerShare>
    <OPRX:TermOfContract contextRef="AsOf2013-06-01_custom_NorthCoastAdvisorsMember">P2Y</OPRX:TermOfContract>
    <OPRX:TermOfContract contextRef="AsOf2012-06-01_custom_NorthCoastAdvisorsMember">P2Y</OPRX:TermOfContract>
    <OPRX:TermOfContract contextRef="AsOf2014-01-02_custom_VicisCapitalAgreementAmdtMember">3/31/14</OPRX:TermOfContract>
    <OPRX:TermOfContract contextRef="AsOf2013-12-31_custom_VicisCapitalAgreementMember">12/30/13</OPRX:TermOfContract>
    <us-gaap:PreferredStockTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Series A Preferred&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended December&amp;#160;31, 2008,&#13;35 preferred shares were issued for $3,500,000. Issuance costs totaled $515,000 resulting in net proceeds of $2,985,000. The 35&#13;shares are convertible to 3,500,000 shares of common stock and bear a 10% cumulative dividend. In addition, there was a warrant&#13;issued to purchase 6,000,000 shares of common stock at an exercise price of $2 for a period of seven years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The holders of the preferred stock are entitled&#13;to semi-annual dividends payable on the stated value of the Series A preferred stock at a rate of 10% per annum, which shall be&#13;cumulative, and accrue daily from the issuance date. The dividends may be paid in cash or shares of the Company's common stock&#13;at management&amp;#146;s discretion. If after the conversion eligibility date, the market price for the common stock for any ten consecutive&#13;trading days in which the stock trades for over $2 per share and trading exceeds 100,000 shares per day, the preferred shareholders&#13;can be required to convert their shares to common stock. Each share of Series A preferred stock shall also be convertible at the&#13;option of the holder into that number of shares of common stock of the Company at the stated value of such share at a $1 conversion&#13;price.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The holder may cause this conversion at the&#13;time the shares are eligible for resale by the holder. The conversion price is subject to adjustment as hereinafter provided, at&#13;any time, or from time to time upon the terms and in the manner hereinafter set forth in the shareholder agreement. There is no&#13;conversion expiration date, however, the holder must provide 30 days notice for the registration of the conversion.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May&amp;#160;12, 2010, the Company&amp;#146;s Board&#13;declared and issued 236,598 common shares as payment for all cumulative and current semi-annual dividends. On November&amp;#160;16,&#13;2010, the Company&amp;#146;s Board declared and issued 173,922 common shares for its semi-annual dividend payment. On March&amp;#160;25,&#13;2011, the Company&amp;#146;s Board declared and issued 176,768 common shares for its semi-annual dividend payment. On September&amp;#160;21,&#13;2011, the Company's Board declared and issued 156,306 common shares for its semi-annual dividend payment. The Company has undeclared&#13;dividends that were due in February and September 2012 totaling $350,000 and undeclared dividends of $350,000 that were due in&#13;February and September 2013 for a total undeclared amount of $700,000 as of December&amp;#160;31, 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Series B Preferred&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended December&amp;#160;31, 2010,&#13;15 preferred shares were issued for $1,500,000. The 15 shares are convertible to 1,000,000 shares of common stock and bear a 10%&#13;cumulative dividend. In addition, there was a warrant issued to purchase 3,000,000 shares of common stock at an exercise price&#13;of $3 for a period of seven years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preferred stock was issued for $1,500,000&#13;less associated issuance costs of $350,000 for net proceeds of $1,150,000. Additionally, 3,000,000 common stock warrants were issued&#13;with the preferred stock. Based on the fair values of the preferred stock and common stock warrants on the issue date, $341,100&#13;was allocated to preferred stock and $1,158,900 was allocated to the common stock warrants. Equity issuance costs of $350,000 were&#13;allocated to the preferred stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the quarter ended September&amp;#160;30,&#13;2011, 15 preferred shares were issued to an investor for $1,500,000. The 15 shares are convertible to 1,000,000 shares of common&#13;stock and bear a 10% cumulative dividend. In addition, there was a warrant issued to purchase 1,000,000 shares of common stock&#13;at an exercise price of $3 for a period of seven years. Based on the fair values of the preferred stock and common stock warrants&#13;on the issue date, $855,460 was allocated to preferred stock and $644,540 was allocated to the common stock warrants. See Note&#13;12.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The holders of the preferred stock are entitled&#13;to semi-annual dividends payable on the stated value of the Series B preferred stock at a rate of 10% per annum, which shall be&#13;cumulative, and accrue daily from the issuance date. The dividends may be paid in cash or shares of the Company's common stock&#13;at management&amp;#146;s discretion. If after the conversion eligibility date, the market price for the common stock for any ten consecutive&#13;trading days in which the stock trades for over $2 per share and trading exceeds 100,000 shares per day, the preferred shareholders&#13;can be required to convert their shares to common stock. Each share of Series B preferred stock shall also be convertible at the&#13;option of the holder into that number of shares of common stock of the Company at the stated value of such share at a $1.50 conversion&#13;price.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The holder may cause this conversion at the&#13;time the shares are eligible for resale by the holder. The conversion price is subject to adjustment as hereinafter provided, at&#13;any time, or from time to time upon the terms and in the manner hereinafter set forth in the shareholder agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March&amp;#160;25,&#13;2011, the Company&amp;#146;s Board declared and issued 75,758 common shares for its semi-annual dividend payment. On September&amp;#160;21,&#13;2011, the Company's Board declared and issued 66,988 common shares for its semi-annual dividend payment. The Company has undeclared&#13;dividends that were due in February and September 2012 totaling $150,000 and undeclared dividends of $150,000 that were due in&#13;February and September 2013 for a total undeclared amount of $300,000 as of December&amp;#160;31, 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:PreferredStockTextBlock>
    <OPRX:PreferredStockSeriesASharesIssuedForProceeds contextRef="From2008-01-01to2008-12-31" unitRef="Shares" decimals="INF">35</OPRX:PreferredStockSeriesASharesIssuedForProceeds>
    <OPRX:PreferredStockSeriesAValue contextRef="From2008-01-01to2008-12-31" unitRef="USD" decimals="0">3500000</OPRX:PreferredStockSeriesAValue>
    <OPRX:PreferredStockSeriesAStockIssuanceExpense contextRef="From2008-01-01to2008-12-31" unitRef="USD" decimals="0">515000</OPRX:PreferredStockSeriesAStockIssuanceExpense>
    <OPRX:PreferredStockSeriesAStockNetProceeds contextRef="From2008-01-01to2008-12-31" unitRef="USD" decimals="0">2985000</OPRX:PreferredStockSeriesAStockNetProceeds>
    <OPRX:ConvertiblePreferredStockSeriesASharesIssuedUponConversion contextRef="From2008-01-01to2008-12-31" unitRef="Shares" decimals="INF">3500000</OPRX:ConvertiblePreferredStockSeriesASharesIssuedUponConversion>
    <OPRX:PreferredStockSeriesAStockDividendRatePercentage contextRef="From2008-01-01to2008-12-31" unitRef="Percent" decimals="INF">0.10</OPRX:PreferredStockSeriesAStockDividendRatePercentage>
    <OPRX:CommonStockWarrantsIssuedForPurchase contextRef="From2008-01-01to2008-12-31" unitRef="Shares" decimals="INF">6000000</OPRX:CommonStockWarrantsIssuedForPurchase>
    <OPRX:CommonStockWarrantsIssuedForPurchase contextRef="From2010-01-01to2010-12-31" unitRef="Shares" decimals="INF">3000000</OPRX:CommonStockWarrantsIssuedForPurchase>
    <OPRX:CommonStockWarrantsIssuedForPurchase contextRef="From2011-07-01to2011-09-30" unitRef="Shares" decimals="INF">1000000</OPRX:CommonStockWarrantsIssuedForPurchase>
    <OPRX:CommonStockWarrantsExercisePrice contextRef="From2008-01-01to2008-12-31" unitRef="Shares" decimals="INF">2.00</OPRX:CommonStockWarrantsExercisePrice>
    <OPRX:CommonStockWarrantsExercisePrice contextRef="From2010-01-01to2010-12-31" unitRef="Shares" decimals="INF">3.00</OPRX:CommonStockWarrantsExercisePrice>
    <OPRX:CommonStockWarrantsExercisePrice contextRef="From2011-07-01to2011-09-30" unitRef="Shares" decimals="INF">3.00</OPRX:CommonStockWarrantsExercisePrice>
    <OPRX:CommonStockWarrantsExercisePrice contextRef="From2014-03-16to2014-03-18_custom_SecuritiesSoldUnderAgreementsMember" unitRef="Shares" decimals="INF">1.20</OPRX:CommonStockWarrantsExercisePrice>
    <OPRX:CommonStockWarrantsExpiration contextRef="From2008-01-01to2008-12-31">P7Y</OPRX:CommonStockWarrantsExpiration>
    <OPRX:CommonStockWarrantsExpiration contextRef="From2010-01-01to2010-12-31">P7Y</OPRX:CommonStockWarrantsExpiration>
    <OPRX:CommonStockWarrantsExpiration contextRef="From2011-07-01to2011-09-30">P7Y</OPRX:CommonStockWarrantsExpiration>
    <OPRX:CommonStockWarrantsExpiration contextRef="From2014-03-16to2014-03-18_custom_SecuritiesSoldUnderAgreementsMember">P5Y</OPRX:CommonStockWarrantsExpiration>
    <OPRX:CommonStockSharesIssuedForDividendPaymentForSeriesA contextRef="AsOf2011-03-25" unitRef="Shares" decimals="INF">176768</OPRX:CommonStockSharesIssuedForDividendPaymentForSeriesA>
    <OPRX:CommonStockSharesIssuedForDividendPaymentForSeriesA contextRef="AsOf2011-09-21" unitRef="Shares" decimals="INF">156306</OPRX:CommonStockSharesIssuedForDividendPaymentForSeriesA>
    <OPRX:CommonStockSharesIssuedForDividendPaymentForSeriesA contextRef="AsOf2010-05-12" unitRef="Shares" decimals="INF">236598</OPRX:CommonStockSharesIssuedForDividendPaymentForSeriesA>
    <OPRX:CommonStockSharesIssuedForDividendPaymentForSeriesA contextRef="AsOf2010-11-16" unitRef="Shares" decimals="INF">173922</OPRX:CommonStockSharesIssuedForDividendPaymentForSeriesA>
    <OPRX:PreferredStockSeriesBSharesIssuedForProceeds contextRef="From2010-01-01to2010-12-31" unitRef="Shares" decimals="INF">15</OPRX:PreferredStockSeriesBSharesIssuedForProceeds>
    <OPRX:PreferredStockSeriesBSharesIssuedForProceeds contextRef="From2011-07-01to2011-09-30" unitRef="Shares" decimals="INF">15</OPRX:PreferredStockSeriesBSharesIssuedForProceeds>
    <OPRX:PreferredStockSeriesBValue contextRef="From2010-01-01to2010-12-31" unitRef="USD" decimals="0">1500000</OPRX:PreferredStockSeriesBValue>
    <OPRX:PreferredStockSeriesBValue contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">1500000</OPRX:PreferredStockSeriesBValue>
    <OPRX:ConvertiblePreferredStockSeriesBSharesIssuedUponConversion contextRef="From2010-01-01to2010-12-31" unitRef="Shares" decimals="INF">1000000</OPRX:ConvertiblePreferredStockSeriesBSharesIssuedUponConversion>
    <OPRX:ConvertiblePreferredStockSeriesBSharesIssuedUponConversion contextRef="From2011-07-01to2011-09-30" unitRef="Shares" decimals="INF">1000000</OPRX:ConvertiblePreferredStockSeriesBSharesIssuedUponConversion>
    <OPRX:PreferredStockSeriesBStockDividendRatePercentage contextRef="From2010-01-01to2010-12-31" unitRef="Percent" decimals="INF">.10</OPRX:PreferredStockSeriesBStockDividendRatePercentage>
    <OPRX:PreferredStockSeriesBStockDividendRatePercentage contextRef="From2011-07-01to2011-09-30" unitRef="Percent" decimals="INF">0.10</OPRX:PreferredStockSeriesBStockDividendRatePercentage>
    <OPRX:PreferredStockSeriesBStockIssuanceExpense contextRef="From2010-01-01to2010-12-31" unitRef="USD" decimals="0">350000</OPRX:PreferredStockSeriesBStockIssuanceExpense>
    <OPRX:PreferredStockSeriesBStockNetProceeds contextRef="From2010-01-01to2010-12-31" unitRef="USD" decimals="0">1150000</OPRX:PreferredStockSeriesBStockNetProceeds>
    <OPRX:CommonStockWarrantsIssued contextRef="From2010-01-01to2010-12-31" unitRef="Shares" decimals="INF">3000000</OPRX:CommonStockWarrantsIssued>
    <OPRX:CommonStockWarrantsIssued contextRef="From2014-03-16to2014-03-18_custom_SecuritiesSoldUnderAgreementsMember" unitRef="Shares" decimals="INF">804139</OPRX:CommonStockWarrantsIssued>
    <OPRX:PreferredStockValueOnGrantDate contextRef="From2010-01-01to2010-12-31" unitRef="USD" decimals="0">341100</OPRX:PreferredStockValueOnGrantDate>
    <OPRX:PreferredStockValueOnGrantDate contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">855460</OPRX:PreferredStockValueOnGrantDate>
    <OPRX:CommonStockWarrantValueOnGrantDate contextRef="From2010-01-01to2010-12-31" unitRef="USD" decimals="0">1158900</OPRX:CommonStockWarrantValueOnGrantDate>
    <OPRX:CommonStockWarrantValueOnGrantDate contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">644540</OPRX:CommonStockWarrantValueOnGrantDate>
    <OPRX:CommonStockSharesIssuedForDividendPaymentForSeriesB contextRef="AsOf2011-03-25" unitRef="Shares" decimals="INF">75758</OPRX:CommonStockSharesIssuedForDividendPaymentForSeriesB>
    <OPRX:CommonStockSharesIssuedForDividendPaymentForSeriesB contextRef="AsOf2011-09-21" unitRef="Shares" decimals="INF">66988</OPRX:CommonStockSharesIssuedForDividendPaymentForSeriesB>
    <OPRX:UndeclaredDividendsPreferredStockValue contextRef="AsOf2012-02-29_us-gaap_SeriesAMember" unitRef="USD" decimals="0">350000</OPRX:UndeclaredDividendsPreferredStockValue>
    <OPRX:UndeclaredDividendsPreferredStockValue contextRef="AsOf2012-12-31_us-gaap_SeriesAMember" unitRef="USD" decimals="0">350000</OPRX:UndeclaredDividendsPreferredStockValue>
    <OPRX:UndeclaredDividendsPreferredStockValue contextRef="AsOf2013-12-31_us-gaap_SeriesAMember" unitRef="USD" decimals="0">700000</OPRX:UndeclaredDividendsPreferredStockValue>
    <OPRX:UndeclaredDividendsPreferredStockValue contextRef="AsOf2012-02-29_us-gaap_SeriesBMember" unitRef="USD" decimals="0">150000</OPRX:UndeclaredDividendsPreferredStockValue>
    <OPRX:UndeclaredDividendsPreferredStockValue contextRef="AsOf2012-12-31_us-gaap_SeriesBMember" unitRef="USD" decimals="0">150000</OPRX:UndeclaredDividendsPreferredStockValue>
    <OPRX:UndeclaredDividendsPreferredStockValue contextRef="AsOf2013-12-31_us-gaap_SeriesBMember" unitRef="USD" decimals="0">300000</OPRX:UndeclaredDividendsPreferredStockValue>
    <OPRX:StockOptionsWarrantsTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for employee stock-based&#13;compensation in accordance with the guidance of ASC Topic 718: Compensation - Stock Compensation, which requires all share-based&#13;payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their&#13;fair values.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows ASC Topic 505-50, formerly&#13;EITF 96-18, &amp;#147;Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with&#13;Selling Goods and Services,&amp;#148; for stock options and warrants issued to consultants and other non-employees. In accordance&#13;with ASC Topic 505-50, these stock options and warrants issued as compensation for services provided to the Company are accounted&#13;for based upon the fair value of the services provided or the estimated fair market value of the option or warrant, whichever can&#13;be more clearly determined. The fair value of the equity instrument is charged directly to compensation expense and additional&#13;paid-in capital over the period during which services are rendered.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May&amp;#160;31, 2011, the Company issued 285,000&#13;stock options to 3 employees at an exercise price of $1.00. The options were valued on the grant date using the Black-Scholes option-pricing&#13;model with the following assumptions: dividend yield of 0%, expected volatility of 218%, risk-free interest rate of 1.68% and expected&#13;life of 60 months. The total value of the options was $320,585. The options vest over one year. The Company recognized share-based&#13;compensation expense of $187,005 during the year ended December 31, 2011. The remaining balance of $133,580 was recognized over&#13;the first five months of 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the quarter ended December&amp;#160;31,&#13;2011, the Company issued 20,000 stock options to 2 employees at an exercise price of $1.00. The options were valued on the grant&#13;date using the Black-Scholes option-pricing model with the following assumptions: dividend yield of 0%, expected volatility of&#13;204-205%, risk-free interest rate of 0.88-0.93% and expected life of 60 months. The total value of the options was $19,270. The&#13;options vest over one year. &lt;font style="background-color: white"&gt;&amp;#160;The Company&amp;#160;recognized share-based compensation expense&#13;of $2,480 and $16,790 during the years ended&amp;#160;December 31,&amp;#160;2012 and 2011&lt;/font&gt;, respectively.&lt;font style="background-color: white"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On November&amp;#160;21, 2011, the Company issued&#13;100,000 stock options to an individual at an exercise price of $0.73. The options were valued on the grant date using the Black-Scholes&#13;option-pricing model with the following assumptions: dividend yield of 0%, expected volatility of 205%, risk-free interest rate&#13;of 0.92% and expected life of 60 months. &lt;font style="background-color: white"&gt;The Company&amp;#160;recognized expenses of $91,811&#13;and $8,346 during the years ended&amp;#160;December&amp;#160;31, 2012 and 2011&lt;/font&gt;, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the quarter ended March&amp;#160;31, 2012,&#13;the Company issued 50,000 stock options to 4 non-employees at an exercise price of $0.89. The options were valued on the grant&#13;date using the Black-Scholes option-pricing model with the following assumptions: dividend yield of 0%, expected volatility of&#13;198%, risk-free interest rate of 0.65% and expected life of 48 months. The total value of the options was $35,091. The options&#13;vest over 4 months. The Company recognized share-based compensation expense of $35,091 during the six months ended June 30, 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the quarter ended December&amp;#160;31,&#13;2012, the Company issued 25,000 stock options to a non-employee at an exercise price of $1.58. The options were valued on the grant&#13;date using the Black-Scholes option-pricing model with the following assumptions: dividend yield of 0%, expected volatility of&#13;200%, risk-free interest rate of 0.67% and expected life of 60 months. The total value of the options was $40,007. The options&#13;vest over 1 year. The Company recognized share-based compensation expense of $31,672 and $8,335 during the years ended December&amp;#160;31,&#13;2013 and 2012, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 30, 2013, the Company issued 50,000&#13;stock options to 6 employees at an exercise price of $1.00. The options were valued on the grant date using the Black-Scholes option-pricing&#13;model with the following assumptions: dividend yield of 0%, expected volatility of 171%, risk-free interest rate of 1.30% and expected&#13;life of 60 months. The total value of the options was $46,322. The options vest over one year. &lt;font style="background-color: white"&gt;&amp;#160;The&#13;Company&amp;#160;recognized share-based compensation expense of $7,720 during the year ended&amp;#160;December 31,&amp;#160;201&lt;/font&gt;3&lt;font style="background-color: white"&gt;.&#13;The remaining balance will be recognized during 2014.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On November 8, 2013, the Company issued 75,000&#13;stock options to 2 non-employees at an exercise price of $1.00. The options were valued on the grant date using the Black-Scholes&#13;option-pricing model with the following assumptions: dividend yield of 0%, expected volatility of 171%, risk-free interest rate&#13;of 1.42% and expected life of 60 months. The total value of the options was $70,961. The options vest over 1 year. The Company&#13;recognized share-based compensation expense of $11,827 during the three months ended December&amp;#160;31, 2013. The remaining balance&#13;of $59,134 has been recorded as deferred stock compensation and will be recognized during 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company had the following options outstanding&#13;as of December&amp;#160;31, 2013:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 50%; border-collapse: collapse; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;Number of Options&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;Weighted average exercise price&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 31%; text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding, January 1, 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 31%; text-align: right"&gt;405,000&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 30%; text-align: right"&gt;1.01&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted - 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;75,000&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.17&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised - 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expired &amp;#150; 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(455,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(.98&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Balance, December 31, 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;25,000&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.58&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted &amp;#150; 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;125,000&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.00&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised &amp;#150; 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expired &amp;#150; 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(25,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(1.58&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Balance, December&amp;#160;31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;125,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;1.00&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company had the following warrants outstanding&#13;as of December&amp;#160;31, 2013:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 50%; border-collapse: collapse; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;Number of Warrants&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;Weighted average exercise price&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 31%; text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding, January 1, 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 31%; text-align: right"&gt;14,344,434&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 30%; text-align: right"&gt;2.41&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted - 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised - 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expired - 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Balance, December 31, 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;14,344,434&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.41&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted - 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised - 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expired - 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(686,100&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(2.71&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Balance, December&amp;#160;31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;13,658,334&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;2.44&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</OPRX:StockOptionsWarrantsTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 50%; border-collapse: collapse; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;Number of Options&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;Weighted average exercise price&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 31%; text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding, January 1, 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 31%; text-align: right"&gt;405,000&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 30%; text-align: right"&gt;1.01&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted - 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;75,000&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.17&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised - 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expired &amp;#150; 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(455,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(.98&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Balance, December 31, 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;25,000&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.58&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted &amp;#150; 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;125,000&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.00&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised &amp;#150; 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expired &amp;#150; 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(25,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(1.58&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Balance, December&amp;#160;31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;125,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;1.00&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <OPRX:ScheduleOfWarrantChangesTableTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 50%; border-collapse: collapse; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;Number of Warrants&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;Weighted average exercise price&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 31%; text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding, January 1, 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 31%; text-align: right"&gt;14,344,434&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 30%; text-align: right"&gt;2.41&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted - 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised - 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expired - 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Balance, December 31, 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;14,344,434&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.41&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted - 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised - 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expired - 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(686,100&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(2.71&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Balance, December&amp;#160;31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;13,658,334&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;2.44&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</OPRX:ScheduleOfWarrantChangesTableTextBlock>
    <OPRX:OptionsIssued contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">125000</OPRX:OptionsIssued>
    <OPRX:OptionsIssued contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">25000</OPRX:OptionsIssued>
    <OPRX:OptionsIssued contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">405000</OPRX:OptionsIssued>
    <OPRX:OptionIssuedPrice contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">1.00</OPRX:OptionIssuedPrice>
    <OPRX:OptionIssuedPrice contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">1.58</OPRX:OptionIssuedPrice>
    <OPRX:OptionIssuedPrice contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">1.01</OPRX:OptionIssuedPrice>
    <OPRX:OptionsGranted contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">125000</OPRX:OptionsGranted>
    <OPRX:OptionsGranted contextRef="From2012-01-01to2012-12-31" unitRef="Shares" decimals="INF">75000</OPRX:OptionsGranted>
    <OPRX:OptionGrantedPrice contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">1.00</OPRX:OptionGrantedPrice>
    <OPRX:OptionGrantedPrice contextRef="From2012-01-01to2012-12-31" unitRef="Shares" decimals="INF">1.17</OPRX:OptionGrantedPrice>
    <OPRX:OptionsExercised contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">0</OPRX:OptionsExercised>
    <OPRX:OptionsExercised contextRef="From2012-01-01to2012-12-31" unitRef="Shares" decimals="INF">0</OPRX:OptionsExercised>
    <OPRX:OptionExercisedPrice contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">0</OPRX:OptionExercisedPrice>
    <OPRX:OptionExercisedPrice contextRef="From2012-01-01to2012-12-31" unitRef="Shares" decimals="INF">0</OPRX:OptionExercisedPrice>
    <OPRX:OptionsExpired contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">-25000</OPRX:OptionsExpired>
    <OPRX:OptionsExpired contextRef="From2012-01-01to2012-12-31" unitRef="Shares" decimals="INF">-455000</OPRX:OptionsExpired>
    <OPRX:OptionExpiredPrice contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">-1.58</OPRX:OptionExpiredPrice>
    <OPRX:OptionExpiredPrice contextRef="From2012-01-01to2012-12-31" unitRef="Shares" decimals="INF">-0.98</OPRX:OptionExpiredPrice>
    <OPRX:WarrantsIssued contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">13658334</OPRX:WarrantsIssued>
    <OPRX:WarrantsIssued contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">14344434</OPRX:WarrantsIssued>
    <OPRX:WarrantsIssued contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">14344434</OPRX:WarrantsIssued>
    <OPRX:WarrantsIssuedPrice contextRef="AsOf2013-12-31" unitRef="USDPShares" decimals="INF">2.44</OPRX:WarrantsIssuedPrice>
    <OPRX:WarrantsIssuedPrice contextRef="AsOf2012-12-31" unitRef="USDPShares" decimals="INF">2.41</OPRX:WarrantsIssuedPrice>
    <OPRX:WarrantsIssuedPrice contextRef="AsOf2011-12-31" unitRef="USDPShares" decimals="INF">2.41</OPRX:WarrantsIssuedPrice>
    <OPRX:WarrantsGranted contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">0</OPRX:WarrantsGranted>
    <OPRX:WarrantsGranted contextRef="From2012-01-01to2012-12-31" unitRef="Shares" decimals="INF">0</OPRX:WarrantsGranted>
    <OPRX:WarrantsGrantedPrice contextRef="From2013-01-01to2013-12-31" unitRef="USDPShares" decimals="INF">0</OPRX:WarrantsGrantedPrice>
    <OPRX:WarrantsGrantedPrice contextRef="From2012-01-01to2012-12-31" unitRef="USDPShares" decimals="INF">0</OPRX:WarrantsGrantedPrice>
    <OPRX:WarrantsExercised contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">0</OPRX:WarrantsExercised>
    <OPRX:WarrantsExercised contextRef="From2012-01-01to2012-12-31" unitRef="Shares" decimals="INF">0</OPRX:WarrantsExercised>
    <OPRX:WarrantsExercisedPrice contextRef="From2013-01-01to2013-12-31" unitRef="USDPShares" decimals="INF">0</OPRX:WarrantsExercisedPrice>
    <OPRX:WarrantsExercisedPrice contextRef="From2012-01-01to2012-12-31" unitRef="USDPShares" decimals="INF">0</OPRX:WarrantsExercisedPrice>
    <OPRX:WarrantsExpired contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">-686100</OPRX:WarrantsExpired>
    <OPRX:WarrantsExpired contextRef="From2012-01-01to2012-12-31" unitRef="Shares" decimals="INF">0</OPRX:WarrantsExpired>
    <OPRX:WarrantsExpiredPrice contextRef="From2013-01-01to2013-12-31" unitRef="USDPShares" decimals="INF">-2.71</OPRX:WarrantsExpiredPrice>
    <OPRX:WarrantsExpiredPrice contextRef="From2012-01-01to2012-12-31" unitRef="USDPShares" decimals="INF">0</OPRX:WarrantsExpiredPrice>
    <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company signed a lease for new office space&#13;on December 1, 2011 at an approximate rent of $5,000 per month. The new offices are in Rochester, Michigan. The lease is for three&#13;years with an option to renew for an additional two years at approximately $5,200 per month with six months advance notice to exercise&#13;the option. Minimum annual rent is as follows for the initial term of the lease:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 35%; border-collapse: collapse; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="width: 77%; padding-bottom: 1pt; text-align: right; padding-left: 5.4pt"&gt;&amp;#160;Year ended December 31, 2014&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; border-bottom: black 1pt solid; text-align: right"&gt;55,542&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right; padding-left: 5.4pt"&gt;Total lease commitment&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;55,542&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
    <us-gaap:ScheduleOfRentExpenseTableTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 35%; border-collapse: collapse; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="width: 77%; padding-bottom: 1pt; text-align: right; padding-left: 5.4pt"&gt;&amp;#160;Year ended December 31, 2014&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; border-bottom: black 1pt solid; text-align: right"&gt;55,542&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right; padding-left: 5.4pt"&gt;Total lease commitment&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;55,542&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfRentExpenseTableTextBlock>
    <OPRX:TermOfLease contextRef="From2013-01-01to2013-12-31">P3Y</OPRX:TermOfLease>
    <us-gaap:OperatingLeasesRentExpenseNet contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">5000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseContingentRentals contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">5200</us-gaap:OperatingLeasesRentExpenseContingentRentals>
    <OPRX:MajorCustomersTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="margin: 0pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company had two major customers that accounted&#13;for 58% and two major customers that accounted for 52% of the Company&amp;#146;s revenues for the years ended December&amp;#160;31, 2013&#13;and 2012, respectively. The Company expects to continue to maintain these relationships with the customers.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p&gt;&lt;/p&gt;</OPRX:MajorCustomersTextBlock>
    <OPRX:MajorCustomers contextRef="From2013-01-01to2013-12-31" unitRef="Percent" decimals="INF">.58</OPRX:MajorCustomers>
    <OPRX:MajorCustomers contextRef="From2012-01-01to2012-12-31" unitRef="Percent" decimals="INF">.52</OPRX:MajorCustomers>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the year ended December&amp;#160;31, 2013,&#13;the Company incurred net income of approximately $216,000 but has no tax liability. The Company began operations in 2007 and has&#13;previous net operating loss carry-forwards of approximately $13,934,000 through December&amp;#160;31, 2012. The cumulative loss of&#13;approximately $13,718,000 will be carried forward and can be used through the year 2033 to offset future taxable income. In the&#13;future, the cumulative net operating loss carry-forward for income tax purposes may differ from the cumulative financial statement&#13;loss due to timing differences between book and tax reporting.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The provision for Federal income tax consists&#13;of the following for the years ended December&amp;#160;31, 2013 and 2012:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/6pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 40%; border-collapse: collapse; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Federal income tax (expense) benefit attributable to:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="width: 54%; text-align: left"&gt;&amp;#160;&amp;#160;Current operations&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;(73,000&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;155,000&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&amp;#160;Valuation allowance&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;73,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(155,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Net provision for federal income tax&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The cumulative tax effect at the expected rate&#13;of 34% of significant items comprising our net deferred tax amount is as follows as of December&amp;#160;31, 2013 and 2012:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 40%; border-collapse: collapse; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Deferred tax asset attributable to:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="width: 54%; text-align: left"&gt;&amp;#160;&amp;#160;Net operating loss carryover&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;4,665,000&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;4,738,000&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&amp;#160;Valuation allowance&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(4,665,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(4,738,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Net deferred tax asset&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Due to the change in ownership provisions of&#13;the Tax Reform Act of 1986, net operating loss carry forwards of approximately $13,718,000 for Federal income tax reporting purposes&#13;are subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited as to use&#13;in future years.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 40%; border-collapse: collapse; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Federal income tax (expense) benefit attributable to:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="width: 54%; text-align: left"&gt;&amp;#160;&amp;#160;Current operations&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;(73,000&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;155,000&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&amp;#160;Valuation allowance&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;73,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(155,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Net provision for federal income tax&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 40%; border-collapse: collapse; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Deferred tax asset attributable to:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="width: 54%; text-align: left"&gt;&amp;#160;&amp;#160;Net operating loss carryover&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;4,665,000&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;4,738,000&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&amp;#160;Valuation allowance&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(4,665,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(4,738,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Net deferred tax asset&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-73000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">155000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">73000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-155000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <OPRX:NetFederalIncomeTax contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">0</OPRX:NetFederalIncomeTax>
    <OPRX:NetFederalIncomeTax contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">0</OPRX:NetFederalIncomeTax>
    <OPRX:OperatingLossCarryForward contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">216000</OPRX:OperatingLossCarryForward>
    <us-gaap:TaxCreditCarryforwardExpirationDate contextRef="From2013-01-01to2013-12-31">2033-01-01</us-gaap:TaxCreditCarryforwardExpirationDate>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2013-01-01to2013-12-31" unitRef="Percent" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">13718000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">13934000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <OPRX:ContingentLiabilityTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 14, 2013, the Company hired a new&#13;CEO. The employment agreement required annual compensation of $175,000 that was to be accrued and deferred until at least January&#13;1, 2014. Additionally, the agreement required the issuance of 2,000,000 options with an exercise price of $1.00 for a term of five&#13;years. The options were not exercisable until at least January 1, 2014, and were only exercisable after reaching certain financial&#13;terms and conditions. Due to these restrictions, no accrual was made for the issuance of these options.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September&amp;#160;20, 2013, the Company entered&#13;into a separation agreement with the CEO. As part of the terms of the separation agreement, the accrued compensation up to the&#13;date of separation was paid and the options were terminated.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</OPRX:ContingentLiabilityTextBlock>
    <OPRX:OperatingExpensesTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Operating expenses consisted of the following&#13;for the years ended December&amp;#160;31, 2013 and 2012, respectively:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in; text-indent: 4.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 45%; border-collapse: collapse; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;Years ended December&amp;#160;31,&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;Years ended December&amp;#160;31,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="width: 54%; padding-left: 5.4pt"&gt;Advertising&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;47,105&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;57,218&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Professional fees&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;552,824&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;263,396&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Consulting&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;100,077&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;19,148&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Salaries, wages and benefits&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,319,712&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,184,367&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Rent&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;60,592&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;62,362&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Depreciation and amortization&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;193,971&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;187,104&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Stock-based compensation&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;411,412&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;285,605&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 5.4pt"&gt;General and administrative&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;288,297&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;269,448&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 5.4pt"&gt;Total Operating Expenses&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;2,973,990&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;2,328,648&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</OPRX:OperatingExpensesTextBlock>
    <OPRX:ScheduleOfOperatingCostAndExpenseByComponentTextBlockTableTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 45%; border-collapse: collapse; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;Years ended December&amp;#160;31,&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;Years ended December&amp;#160;31,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="width: 54%; padding-left: 5.4pt"&gt;Advertising&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;47,105&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;57,218&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Professional fees&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;552,824&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;263,396&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Consulting&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;100,077&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;19,148&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Salaries, wages and benefits&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,319,712&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,184,367&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Rent&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;60,592&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;62,362&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Depreciation and amortization&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;193,971&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;187,104&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Stock-based compensation&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;411,412&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;285,605&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 5.4pt"&gt;General and administrative&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;288,297&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;269,448&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 5.4pt"&gt;Total Operating Expenses&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;2,973,990&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;2,328,648&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</OPRX:ScheduleOfOperatingCostAndExpenseByComponentTextBlockTableTextBlock>
    <us-gaap:AdvertisingExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">47105</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">57218</us-gaap:AdvertisingExpense>
    <us-gaap:ProfessionalFees contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">552824</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">263396</us-gaap:ProfessionalFees>
    <OPRX:Consulting contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">100077</OPRX:Consulting>
    <OPRX:Consulting contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">19148</OPRX:Consulting>
    <us-gaap:SalariesWagesAndOfficersCompensation contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1319712</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1184367</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:PaymentsForRent contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-60592</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-62362</us-gaap:PaymentsForRent>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">288297</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">269448</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;On January&amp;#160;2,&#13;2014 the Company executed an amendment to their securities redemption option agreement with Vicis Capital Master Fund that provides&#13;an option to purchase all of the outstanding shares and derivative securities held by Vicis for a total of $6,000,000. The term&#13;of the option is through March&amp;#160;31, 2014. The original agreement payment was for $9,000,000 and term was through December 30,&#13;2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On&amp;#160;March 17, 2014,&amp;#160;the Company&amp;#160;entered&#13;into a securities purchase agreement, pursuant to which&amp;#160;the Company&amp;#160;sold an aggregate of 8,333,333 shares of&amp;#160;the&#13;Company&amp;#146;s common stock for $1.20 per share, or gross proceeds of $10,000,000.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2014-03-31" unitRef="Shares" decimals="INF">22809586</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2013-12-31" unitRef="USDPShares" decimals="INF">.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2012-12-31" unitRef="USDPShares" decimals="INF">.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">65</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">65</us-gaap:PreferredStockSharesIssued>
    <us-gaap:GrossProfit contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">3189591</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1873726</us-gaap:GrossProfit>
    <us-gaap:OperatingExpenses contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">2973990</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">2328648</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">215601</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-454922</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2012-01-01to2013-12-31_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">-364345</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-246</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-469</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndDebtExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">0</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-100</us-gaap:InterestAndDebtExpense>
    <us-gaap:OtherExpenses contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">246</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">369</us-gaap:OtherExpenses>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">215847</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-454553</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="From2012-01-01to2013-12-31_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">-363976</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">215847</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-454553</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="From2012-01-01to2013-12-31_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">-363976</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">14388017</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="From2012-01-01to2012-12-31" unitRef="Shares" decimals="INF">14211455</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="From2013-01-01to2013-12-31" unitRef="USDPShares" decimals="INF">0.02</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="From2012-01-01to2012-12-31" unitRef="USDPShares" decimals="INF">-0.03</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">14713017</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2012-01-01to2012-12-31" unitRef="Shares" decimals="INF">17211455</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare contextRef="From2013-01-01to2013-12-31" unitRef="USDPShares" decimals="INF">0.01</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare contextRef="From2012-01-01to2012-12-31" unitRef="USDPShares" decimals="INF">-0.03</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">49618</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <OPRX:StockOptionsIssuedForServices contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">19547</OPRX:StockOptionsIssuedForServices>
    <OPRX:StockOptionsIssuedForServices contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">40007</OPRX:StockOptionsIssuedForServices>
    <us-gaap:Revenues contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">4957016</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1989086</us-gaap:Revenues>
    <us-gaap:RestatementToPriorYearIncomeTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the quarter ended December 31, 2013,&#13;the Company corrected an accounting error related to revenue share expenses. The Company will accrue the expense for amounts due,&#13;versus when they are paid, for proper matching. The revenue share expense was not properly accrued at the end of 2012 or at the&#13;end of each 2013 quarter&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The restated Consolidated Balance Sheet, Consolidated&#13;Statement of Operations and Consolidated Statement of Cash Flows for the year ended December 31, 2012 is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 50%; border-collapse: collapse; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;Year ended December 31, 2012&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: left; padding-left: 5.4pt"&gt;Financial Statement&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: left; padding-left: 5.4pt"&gt;Line Item&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Corrected&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Previously Stated&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="width: 30%; text-align: left; padding-left: 5.4pt"&gt;Balance sheet&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 29%; padding-left: 5.4pt"&gt;Revenue share payable&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right"&gt;90,577&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Income statement&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Revenue share expense&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;115,360&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;24,783&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Income statement&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Loss from operations&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(454,922&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(364,345&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Income statement&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Loss before provision for income taxes&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(454,553&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(363,976&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Income statement&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Net loss&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(454,553&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(363,976&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Statement of cash flows&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Net loss&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(454,553&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(363,976&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Statement of cash flows&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Increase in revenue share payable&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;90,577&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:RestatementToPriorYearIncomeTextBlock>
    <OPRX:RestatementToPriorYearIncomePolicyTableTextBlock contextRef="From2013-01-01to2013-12-31">&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 50%; border-collapse: collapse; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;Year ended December 31, 2012&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: left; padding-left: 5.4pt"&gt;Financial Statement&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: left; padding-left: 5.4pt"&gt;Line Item&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Corrected&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Previously Stated&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="width: 30%; text-align: left; padding-left: 5.4pt"&gt;Balance sheet&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 29%; padding-left: 5.4pt"&gt;Revenue share payable&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right"&gt;90,577&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Income statement&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Revenue share expense&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;115,360&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;24,783&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Income statement&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Loss from operations&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(454,922&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(364,345&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Income statement&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Loss before provision for income taxes&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(454,553&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(363,976&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Income statement&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Net loss&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(454,553&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(363,976&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Statement of cash flows&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Net loss&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(454,553&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(363,976&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Statement of cash flows&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Increase in revenue share payable&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;90,577&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</OPRX:RestatementToPriorYearIncomePolicyTableTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif"&gt;The preparation of financial statements in conformity with generally accepted&#13;accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities&#13;at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates&#13;and assumptions have been made in determining the depreciable lives of such assets and the allowance for doubtful accounts receivable.&#13;Actual results could differ from these estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;The Company&amp;#146;s&#13;key members are part of a continual research development team and monitor new technologies, trends, services and partnerships that&#13;can provide the Company with additional services, value to healthcare and pharmaceutical industries and to the patients it serves.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.25in 0 0; letter-spacing: -0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.1pt; text-align: justify"&gt;The Company seeks to&#13;educate team members through understanding of all market dynamics that have the potential to affect the business both short term&#13;and longer term. The primary goal is to help patients better afford and access the medicines their doctor prescribes, as well as&#13;other healthcare products and services they need. Based on this, the Company continually seeks better ways to meet this mission&#13;through technology, better user experiences and new ways to engage industries to provide new support for patients needing their&#13;products. The Company is always seeking new services and solutions to offer. At this time, the three current platforms provide&#13;robust opportunities and growth during the next five years.&lt;/p&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">6923</us-gaap:ProvisionForDoubtfulAccounts>
    <OPRX:RevenueShareTransactionValueMinimum contextRef="From2013-01-01to2013-12-31" unitRef="Percent" decimals="INF">.25</OPRX:RevenueShareTransactionValueMinimum>
    <OPRX:RevenueShareTransactionValueMaximum contextRef="From2013-01-01to2013-12-31" unitRef="Percent" decimals="INF">.50</OPRX:RevenueShareTransactionValueMaximum>
    <OPRX:NewPatentsAndTrademarks contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">62595</OPRX:NewPatentsAndTrademarks>
    <OPRX:NewPatentsAndTrademarks contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">0</OPRX:NewPatentsAndTrademarks>
    <us-gaap:DeferredRevenue contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">4252</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">49252</us-gaap:DeferredRevenue>
    <OPRX:MinimumAnnualRent contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">55542</OPRX:MinimumAnnualRent>
    <OPRX:TotalLeaseCommitment contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">55542</OPRX:TotalLeaseCommitment>
    <OPRX:AdditionalRenewalOption contextRef="From2013-01-01to2013-12-31">P2Y</OPRX:AdditionalRenewalOption>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">4665000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">4738000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">-4665000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">-4738000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsNet>
    <OPRX:AnnualCompensationForCeo contextRef="AsOf2013-01-14" unitRef="USD" decimals="0">175000</OPRX:AnnualCompensationForCeo>
    <OPRX:IssuanceOfStockOptionsToCeoShares contextRef="AsOf2013-01-14" unitRef="Shares" decimals="INF">2000000</OPRX:IssuanceOfStockOptionsToCeoShares>
    <OPRX:IssuanceOfStockOptionsToCeoParValue contextRef="AsOf2013-01-14" unitRef="Shares" decimals="INF">1.00</OPRX:IssuanceOfStockOptionsToCeoParValue>
    <OPRX:TermOfOptionsAgreement contextRef="AsOf2013-01-14">P5Y</OPRX:TermOfOptionsAgreement>
    <OPRX:ExercisableDate contextRef="AsOf2013-01-14">2014-01-01</OPRX:ExercisableDate>
    <dei:EntityPublicFloat contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">15276153</dei:EntityPublicFloat>
    <us-gaap:AccruedFeesAndOtherRevenueReceivable contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">-1193661</us-gaap:AccruedFeesAndOtherRevenueReceivable>
    <us-gaap:AccruedFeesAndOtherRevenueReceivable contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">-90577</us-gaap:AccruedFeesAndOtherRevenueReceivable>
    <us-gaap:AccruedFeesAndOtherRevenueReceivable contextRef="AsOf2012-12-31_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">0</us-gaap:AccruedFeesAndOtherRevenueReceivable>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">2039368</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">1404882</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">1589170</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2011-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2011-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">14192</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">14232</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">14773</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2011-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">20826934</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">20058051</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">18148049</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2011-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">5125558</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">6164666</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">8726708</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2011-12-31_us-gaap_DeferredCompensationShareBasedPaymentsMember" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31_us-gaap_DeferredCompensationShareBasedPaymentsMember" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31_us-gaap_DeferredCompensationShareBasedPaymentsMember" unitRef="USD" decimals="0">-233942</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2011-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-24377514</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-24832067</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-24616220</us-gaap:StockholdersEquity>
    <OPRX:StockOptionsIssuedToEmployees contextRef="From2012-01-01to2012-12-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">150367</OPRX:StockOptionsIssuedToEmployees>
    <OPRX:StockOptionsIssuedToEmployees contextRef="From2013-01-01to2013-12-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">7720</OPRX:StockOptionsIssuedToEmployees>
    <OPRX:StockOptionsIssuedToEmployees contextRef="From2012-01-01to2012-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">150367</OPRX:StockOptionsIssuedToEmployees>
    <OPRX:StockIssuedForServicesShares contextRef="From2012-01-01to2012-12-31_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">40000</OPRX:StockIssuedForServicesShares>
    <OPRX:StockIssuedForServicesShares contextRef="From2013-01-01to2013-12-31_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">40000</OPRX:StockIssuedForServicesShares>
    <OPRX:StockIssuedForServicesShares contextRef="From2012-01-01to2012-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">44760</OPRX:StockIssuedForServicesShares>
    <OPRX:StockIssuedForServicesShares contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">68860</OPRX:StockIssuedForServicesShares>
    <OPRX:StockIssuedForServicesValue contextRef="From2012-01-01to2012-12-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">40</OPRX:StockIssuedForServicesValue>
    <OPRX:StockIssuedForServicesValue contextRef="From2013-01-01to2013-12-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">40</OPRX:StockIssuedForServicesValue>
    <OPRX:StockIssuedForServicesValue contextRef="From2012-01-01to2012-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">44800</OPRX:StockIssuedForServicesValue>
    <OPRX:StockIssuedForServicesValue contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">68900</OPRX:StockIssuedForServicesValue>
    <OPRX:IssuanceOfStockOptionsToEmployeesShares contextRef="From2012-01-01to2012-12-31_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">150367</OPRX:IssuanceOfStockOptionsToEmployeesShares>
    <OPRX:IssuanceOfStockOptionsToEmployeesShares contextRef="From2013-01-01to2013-12-31_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">7720</OPRX:IssuanceOfStockOptionsToEmployeesShares>
    <OPRX:IssuanceOfStockOptionsForServicesShares contextRef="From2012-01-01to2012-12-31_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">75098</OPRX:IssuanceOfStockOptionsForServicesShares>
    <OPRX:IssuanceOfStockOptionsForServicesShares contextRef="From2013-01-01to2013-12-31_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">70961</OPRX:IssuanceOfStockOptionsForServicesShares>
    <OPRX:IssuanceOfStockOptionsForServicesShares contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">11827</OPRX:IssuanceOfStockOptionsForServicesShares>
    <OPRX:IssuanceOfStockOptionsForServicesAmount contextRef="From2012-01-01to2012-12-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">75098</OPRX:IssuanceOfStockOptionsForServicesAmount>
    <OPRX:IssuanceOfStockOptionsForServicesAmount contextRef="From2013-01-01to2013-12-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">-59134</OPRX:IssuanceOfStockOptionsForServicesAmount>
    <OPRX:ReclassificationForOptionsPreviouslyRecordedAsWarrants contextRef="From2012-01-01to2012-12-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">768883</OPRX:ReclassificationForOptionsPreviouslyRecordedAsWarrants>
    <OPRX:ReclassificationForOptionsPreviouslyRecordedAsWarrants contextRef="From2013-01-01to2013-12-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">1910002</OPRX:ReclassificationForOptionsPreviouslyRecordedAsWarrants>
    <OPRX:ReclassificationForOptionsPreviouslyRecordedAsWarrantsShares contextRef="From2012-01-01to2012-12-31_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">-768883</OPRX:ReclassificationForOptionsPreviouslyRecordedAsWarrantsShares>
    <OPRX:ReclassificationForOptionsPreviouslyRecordedAsWarrantsShares contextRef="From2013-01-01to2013-12-31_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">-1910002</OPRX:ReclassificationForOptionsPreviouslyRecordedAsWarrantsShares>
    <OPRX:ReclassificationForOptionsPreviouslyRecordedAsWarrantsShares contextRef="From2012-01-01to2012-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">0</OPRX:ReclassificationForOptionsPreviouslyRecordedAsWarrantsShares>
    <OPRX:ReclassificationForOptionsPreviouslyRecordedAsWarrantsShares contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">0</OPRX:ReclassificationForOptionsPreviouslyRecordedAsWarrantsShares>
    <OPRX:IssuanceOfCommonStockForEmploymentSeveranceShares contextRef="From2013-01-01to2013-12-31_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">500000</OPRX:IssuanceOfCommonStockForEmploymentSeveranceShares>
    <OPRX:IssuanceOfCommonStockForEmploymentSeveranceShares contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">504500</OPRX:IssuanceOfCommonStockForEmploymentSeveranceShares>
    <OPRX:IssuanceOfCommonStockForEmploymentSeveranceShares contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">0</OPRX:IssuanceOfCommonStockForEmploymentSeveranceShares>
    <OPRX:IssuanceOfCommonStockForEmploymentSeveranceAmount contextRef="From2013-01-01to2013-12-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">500</OPRX:IssuanceOfCommonStockForEmploymentSeveranceAmount>
    <OPRX:IssuanceOfCommonStockForEmploymentSeveranceAmount contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">-505000</OPRX:IssuanceOfCommonStockForEmploymentSeveranceAmount>
    <OPRX:IssuanceOfCommonStockForCorrectionOfPriorIssueShares contextRef="From2013-01-01to2013-12-31_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">1000</OPRX:IssuanceOfCommonStockForCorrectionOfPriorIssueShares>
    <OPRX:IssuanceOfCommonStockForCorrectionOfPriorIssueShares contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">-1</OPRX:IssuanceOfCommonStockForCorrectionOfPriorIssueShares>
    <OPRX:IssuanceOfCommonStockForCorrectionOfPriorIssueAmount contextRef="From2013-01-01to2013-12-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">1</OPRX:IssuanceOfCommonStockForCorrectionOfPriorIssueAmount>
    <OPRX:IssuanceOfCommonStockForCorrectionOfPriorIssueAmount contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">0</OPRX:IssuanceOfCommonStockForCorrectionOfPriorIssueAmount>
    <OPRX:ConsultingServicesExpenseShares contextRef="From2013-01-01to2013-12-31_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">330192</OPRX:ConsultingServicesExpenseShares>
    <OPRX:ConsultingServicesExpenseAmount contextRef="From2013-01-01to2013-12-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">330192</OPRX:ConsultingServicesExpenseAmount>
    <OPRX:NetIncomeLossShares contextRef="From2012-01-01to2012-12-31_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">-454553</OPRX:NetIncomeLossShares>
    <OPRX:NetIncomeLossShares contextRef="From2013-01-01to2013-12-31_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">215847</OPRX:NetIncomeLossShares>
    <OPRX:RevenueShareExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1767425</OPRX:RevenueShareExpense>
    <OPRX:RevenueShareExpense contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">115360</OPRX:RevenueShareExpense>
    <OPRX:RevenueShareExpense contextRef="From2012-01-01to2013-12-31_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">24783</OPRX:RevenueShareExpense>
    <OPRX:RevenueSharePayable contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1103084</OPRX:RevenueSharePayable>
    <OPRX:RevenueSharePayable contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">90577</OPRX:RevenueSharePayable>
    <OPRX:RevenueSharePayable contextRef="From2012-01-01to2013-12-31_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">0</OPRX:RevenueSharePayable>
    <OPRX:ConvertiblePreferredStockSeriesDescription contextRef="From2008-01-01to2008-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The holders of the&#13;preferred stock are entitled to semi-annual dividends payable on the stated value of the Series A preferred stock at a rate of&#13;10% per annum, which shall be cumulative, and accrue daily from the issuance date. The dividends may be paid in cash or shares&#13;of the Company's common stock at management&amp;#146;s discretion. If after the conversion eligibility date, the market price for&#13;the common stock for any ten consecutive trading days in which the stock trades for over $2 per share and trading exceeds 100,000&#13;shares per day, the preferred shareholders can be required to convert their shares to common stock. Each share of Series A preferred&#13;stock shall also be convertible at the option of the holder into that number of shares of common stock of the Company at the stated&#13;value of such share at a $1 conversion price.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The holder may cause&#13;this conversion at the time the shares are eligible for resale by the holder. The conversion price is subject to adjustment as&#13;hereinafter provided, at any time, or from time to time upon the terms and in the manner hereinafter set forth in the shareholder&#13;agreement. There is no conversion expiration date, however, the holder must provide 30 days notice for the registration of the&#13;conversion.&lt;/font&gt;&lt;/p&gt;</OPRX:ConvertiblePreferredStockSeriesDescription>
    <OPRX:ConvertiblePreferredStockSeriesDescription contextRef="From2011-07-01to2011-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The holders of the preferred stock are entitled&#13;to semi-annual dividends payable on the stated value of the Series B preferred stock at a rate of 10% per annum, which shall be&#13;cumulative, and accrue daily from the issuance date. The dividends may be paid in cash or shares of the Company's common stock&#13;at management&amp;#146;s discretion. If after the conversion eligibility date, the market price for the common stock for any ten consecutive&#13;trading days in which the stock trades for over $2 per share and trading exceeds 100,000 shares per day, the preferred shareholders&#13;can be required to convert their shares to common stock. Each share of Series B preferred stock shall also be convertible at the&#13;option of the holder into that number of shares of common stock of the Company at the stated value of such share at a $1.50 conversion&#13;price.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The holder may cause this conversion at the&#13;time the shares are eligible for resale by the holder. The conversion price is subject to adjustment as hereinafter provided, at&#13;any time, or from time to time upon the terms and in the manner hereinafter set forth in the shareholder agreement.&lt;/p&gt;</OPRX:ConvertiblePreferredStockSeriesDescription>
    <OPRX:StockOptionsIssued contextRef="AsOf2011-05-31_ThreeEmployeesStockOptionsMember" unitRef="USD" decimals="0">285000</OPRX:StockOptionsIssued>
    <OPRX:StockOptionsIssued contextRef="AsOf2011-12-31_TwoEmployeesStockOptionsMember" unitRef="USD" decimals="0">20000</OPRX:StockOptionsIssued>
    <OPRX:StockOptionsIssued contextRef="AsOf2011-11-21_IndividualStockOptionsMember" unitRef="USD" decimals="0">100000</OPRX:StockOptionsIssued>
    <OPRX:StockOptionsIssued contextRef="AsOf2012-03-31_FourNonEmployeesStockOptionsMember" unitRef="USD" decimals="0">50000</OPRX:StockOptionsIssued>
    <OPRX:StockOptionsIssued contextRef="AsOf2012-12-31_NonEmployeeStockOptionsMember" unitRef="USD" decimals="0">25000</OPRX:StockOptionsIssued>
    <OPRX:StockOptionsIssued contextRef="AsOf2013-10-30_custom_SixEmployeesStockOptionsMember" unitRef="USD" decimals="0">50000</OPRX:StockOptionsIssued>
    <OPRX:StockOptionsIssued contextRef="AsOf2013-11-08_custom_TwoNonEmployeeStockOptionsMember" unitRef="USD" decimals="0">75000</OPRX:StockOptionsIssued>
    <OPRX:StockOptionExercisePricePerShare contextRef="AsOf2011-05-31_ThreeEmployeesStockOptionsMember" unitRef="Shares" decimals="INF">1.00</OPRX:StockOptionExercisePricePerShare>
    <OPRX:StockOptionExercisePricePerShare contextRef="AsOf2011-12-31_TwoEmployeesStockOptionsMember" unitRef="Shares" decimals="INF">1.00</OPRX:StockOptionExercisePricePerShare>
    <OPRX:StockOptionExercisePricePerShare contextRef="AsOf2011-11-21_IndividualStockOptionsMember" unitRef="Shares" decimals="INF">0.73</OPRX:StockOptionExercisePricePerShare>
    <OPRX:StockOptionExercisePricePerShare contextRef="AsOf2012-03-31_FourNonEmployeesStockOptionsMember" unitRef="Shares" decimals="INF">0.89</OPRX:StockOptionExercisePricePerShare>
    <OPRX:StockOptionExercisePricePerShare contextRef="AsOf2012-12-31_NonEmployeeStockOptionsMember" unitRef="Shares" decimals="INF">1.58</OPRX:StockOptionExercisePricePerShare>
    <OPRX:StockOptionExercisePricePerShare contextRef="AsOf2013-10-30_custom_SixEmployeesStockOptionsMember" unitRef="Shares" decimals="INF">1.00</OPRX:StockOptionExercisePricePerShare>
    <OPRX:StockOptionExercisePricePerShare contextRef="AsOf2013-11-08_custom_TwoNonEmployeeStockOptionsMember" unitRef="Shares" decimals="INF">1.00</OPRX:StockOptionExercisePricePerShare>
    <OPRX:StockOptionValueBlackScholesModel contextRef="AsOf2011-12-31_TwoEmployeesStockOptionsMember" unitRef="USD" decimals="0">19270</OPRX:StockOptionValueBlackScholesModel>
    <OPRX:StockOptionValueBlackScholesModel contextRef="AsOf2012-03-31_FourNonEmployeesStockOptionsMember" unitRef="USD" decimals="0">35091</OPRX:StockOptionValueBlackScholesModel>
    <OPRX:StockOptionValueBlackScholesModel contextRef="AsOf2012-12-31_NonEmployeeStockOptionsMember" unitRef="USD" decimals="0">40007</OPRX:StockOptionValueBlackScholesModel>
    <OPRX:StockOptionValueBlackScholesModel contextRef="AsOf2013-10-30_custom_SixEmployeesStockOptionsMember" unitRef="USD" decimals="0">46322</OPRX:StockOptionValueBlackScholesModel>
    <OPRX:StockOptionValueBlackScholesModel contextRef="AsOf2013-11-08_custom_TwoNonEmployeeStockOptionsMember" unitRef="USD" decimals="0">70961</OPRX:StockOptionValueBlackScholesModel>
    <OPRX:StockOptionVestingPeriod contextRef="AsOf2011-12-31_TwoEmployeesStockOptionsMember">P1Y</OPRX:StockOptionVestingPeriod>
    <OPRX:StockOptionVestingPeriod contextRef="AsOf2012-03-31_FourNonEmployeesStockOptionsMember">P4M</OPRX:StockOptionVestingPeriod>
    <OPRX:StockOptionVestingPeriod contextRef="AsOf2012-12-31_NonEmployeeStockOptionsMember">P1Y</OPRX:StockOptionVestingPeriod>
    <OPRX:StockOptionVestingPeriod contextRef="AsOf2013-10-30_custom_SixEmployeesStockOptionsMember">P1Y</OPRX:StockOptionVestingPeriod>
    <OPRX:StockOptionVestingPeriod contextRef="AsOf2013-11-08_custom_TwoNonEmployeeStockOptionsMember">P1Y</OPRX:StockOptionVestingPeriod>
    <OPRX:DebtRedemptionLongtermDebtAmount contextRef="AsOf2014-01-02_custom_VicisCapitalAgreementAmdtMember" unitRef="USD" decimals="0">6000000</OPRX:DebtRedemptionLongtermDebtAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2013-12-31_custom_VicisCapitalAgreementMember" unitRef="USD" decimals="0">9000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:CommonStockSharesSubscriptions contextRef="AsOf2014-03-17_custom_SecuritiesSoldUnderAgreementsMember" unitRef="USD" decimals="0">10000000</us-gaap:CommonStockSharesSubscriptions>
    <us-gaap:AccruedSalesCommissionCurrent contextRef="AsOf2014-03-17_custom_SecuritiesSoldUnderAgreementsMember" unitRef="USD" decimals="0">970000</us-gaap:AccruedSalesCommissionCurrent>
    <us-gaap:LitigationSettlementExpense contextRef="From2014-02-28to2014-03-18_custom_LDMSettlementAgreementMember" unitRef="USD" decimals="0">400000</us-gaap:LitigationSettlementExpense>
</xbrli:xbrl>
